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Abstract 
 
Background: Expression of Forssman antigen (FORS1) has been recently described on 
human erythrocytes and consequently the FORS blood group system was recognized as the 
31st system. 
Objective: To investigate the expression of FORS1 antigen in human erythrocytes and 
characterize anti-Forssman antibody among Palestinian population and compare it to a group 
of European donors.  
Methods and Materials: In  this  study,  211  adult and 73 newborn donors  from  Palestine  
and  65  adult donors from  Europe  were  included.  The RBCs from the Palestinian donors 
were typed for FORS1 antigen using monoclonal anti-Fs antibodies and plasma were tested 
for anti-Forssman antibody using sheep RBCs.  The molecular biology of FORS1 antigen 
negativity was investigated by DNA sequencing of exon 7 of GBGT1 gene that encodes the 
Fs synthetase, the enzyme that catalyzes the terminal step of FORS1 antigen biosynthesis. 
Results: All study samples tested were negative for FORS1 antigen by serologic typing. 
Anti-Fs antibodies (IgG and IgM) were present in 96.2 % of adult Palestinian samples. The 
absence of anti-Fs was more common among males compared to females, and stronger 
reactions (agglutinations) were observed also in females. Stronger agglutination reactions 
(grades +3 or +4) for IgG and IgM anti-Fs were observed in A and O blood groups, 50% and 
50.6%, respectively, compared to other blood groups. DNA sequencing of exon 7 of GBGT1 
gene revealed that all samples have the 887A>G [p.Gln296Arg] and 688G>A [p.Gly230Ser] 
mutations which were previously reported to be responsible for the FORS1 antigen 
negativity. Additionally, four SNPs were detected with an allele frequency ranging from 
0.2% to 3.6%. One SNP, namely R243C is a novel mutation detected in a Palestinian donor 
and has a damaging effect on the Fs synthetase as predicted by PolyPhen-2. There was no 
significant difference between presence/absence of anti-Forssman IgM (P= 0.408) and IgG 
(P= 0.433) antibodies and GBGT1 gene polymorphisms.  
Conclusion: This is the first study to investigate FORS blood group system in Palestine. 
Our results confirmed that the FORS is a low prevalence blood group system - at least 
 
 
V 
 
among our studied populations- with naturally occurring anti-Forssman in the majority of 
adult donors. A novel missense mutation (R243C) with damaging effect on Fs sythetase has 
been detected in a Palestinian donor. 
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Chapter One 
Introduction 
 
1.1  Background 
 
Transfusion is an important tool for preventive and curative therapy in case of 
hemorrhage or blood loss due to traumatic injury or surgery. Several adverse health 
effects from blood transfusion can occur, such as an increased risk of cancer and 
transfusion-transmitted diseases [1]. Still the main risk of transfusion is blood 
mismatching due to presence of different blood group antigens on the donor and recipient 
red blood cells [2]. Dangerous consequences of blood transfusion for recipients ranges 
from hemolytic transfusion reactions to death [3]. The antigens are not restricted to the 
surface of erythrocytes, they are also found in other body fluids such as semen and saliva, 
as well as on other cells, tissues and organs. So, it is essential to take different blood 
groups into account in transfusion and  transplantation [4]. Indeed, knowledge gained 
from studying blood groups have contributed to the development in several aspects in 
genetics, evolution, and biology [5]. 
 
The ABO and Rh blood group systems are the most common blood groups but they are 
just two of more than 30 blood group systems known so far.  At present more than 350 
blood group antigens has been recognized, and the list of these antigens is continuously 
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updated at online:  http://www.ncbi.nlm.nih.gov/projects/gv/rbc/xslcgi.fcgi?cmd=bgmut 
[6]. All antigens fall into one of four classifications; 297 antigens within 35 systems, 50 
antigens within collections (200 series), low incidence antigens (700 series), and high 
incidence antigens (901 series) [7, 8]. 
 
Nowadays, new subgroups and weak subgroups have been discovered are basically due 
to recognized genetic mutations in most cases [6] . Weak ABO subgroups are defined by 
individuals whose erythrocytes give weaker reactions or are nonreactive serologically 
with antisera than those of common subgroups [9]. They result from the respective 
mutated ABO gene due to the expression of an alternate weak allele present at the ABO 
loci. Even though the weak subgroups are rare phenotypes, and account for a minority of 
individuals, still we need to define them by confirmatory tests other than ABO forward 
and reverse typing and may include ABO genotyping [4]. On one hand, these subgroups 
give weak reactions, but they still can have serious consequences after multiple 
transfusions of patients with blood disorders, on the other hand, identification of these 
subgroups is important because they are  keys for the discovery of their respective blood 
group systems and may be mistyped as group O [9]. 
 
Apae, a rare phenotype was classified in 1987 as an A subgroup, “where “p” designates its 
reaction with the lectin Helix pomatia and “ae” reflects the absorption and elution of only 
certain human anti-A serum” [10]. It was discovered in three unrelated UK families who 
were blood group O and had the genotype O1/O1 [11, 12]. It was distinguished from other 
A variants by several methods, such as  its agglutination with only certain human anti-A 
and anti-A,B sera and their red cells reacted with anti-A lectin prepared from Helix 
pomatia [10]. Two decades later, this A-like expression on the RBCs was reinvestigated 
using genomic and biochemical methods [12]. 
 
In July 2012, Apae blood type was the key to the discovery of a Forssman antigen 
(FORS1) in normal human hematopoietic tissue in Sweden, by researchers at Gothenburg 
University and Lund University [12, 13]. This was initiated because the Apae phenotype 
was shown to be homozygous for common deletional O alleles, despite the expression of 
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the A-like antigen. Single heterozygous polymorphism c.887G > A (R296Q) was found 
in the Globoside alpha-1,3-N-acetylGalactosaminyl Transferase 1 (GBGT1) gene that 
makes the human Forssman synthase active [12]. This mutation causes substitution of the 
amino acid Arginine at codon 296 by Glutamine, the same amino acid observed in 
Forssman antigen positive animals. 
 
Immunochemical and mass spectrophotometric studies demonstrated the presence of the 
Forssman glycolipid on these RBC. Thus, Apae became an old terminology and it was 
abolished and replaced by the International Society of Blood Transfusion (ISBT) by  
newly formed 31st blood-group system given the name  FORS [7, 12]. 
 
 All the criteria for a blood group system which include: independency of other blood 
group antigen, be inheritable,  be expressed on red blood cells, and presence of naturally-
occurring antibodies were achieved for the FORS 1 antigen [7, 14]. So, the FORS system 
will now be a further factor to consider in blood transfusions and may lead to serious 
reactions in transfusions/transplantations, if anti-FORS1 positive plasma is donated to a 
FORS1 positive patient.  
 
 
Until now, 35 blood group systems were discovered. Five of them were discovered in the 
past 2 years and ratified by the ISBT meeting in Cancun, July 2012; FORS (#31), JR 
(#32), LAN (#33), Vel, and the complement protein, CD59 [15, 16]. Figure 1.1 shows the 
date of discovery of blood group systems according to the date of discovery of the first 
antigen in the system. See also blood group systems in appendix A. 
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Figure 1.1  Date of discovery of blood group systems according to the date of discovery of 
the first antigen in the system [17]. The figure was modified by adding Vel and CD95. HRF; 
homologous restriction factor and is a synonym for the complement regulation protein CD59. 
 
1.2   Forssman Antigen Story 
 
The Forssman (FORS1) antigen was first described in 1911 by a pioneer Swedish 
Pathologist John Frederick Forssman (1868 – 1947) [18], so the discovery recently 
celebrated its 104th birthday. It was acknowledged after injection of rabbits with a 
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suspension of kidney tissue from guinea pig and the rabbits produced antibodies that 
were capable of hemolysing sheep erythrocytes [19].  
 
FORS1 antigen is one of a set of 13 glycosphingolipids (GSLs), all of which have in 
common a core of galactosyl-(a1,3) galactose moiety [20]. They include the FORS1, 
P1PK and the GLOB blood group collection and are also closely related with respect to 
their structure and biosynthesis [13, 21]. FORS1 is a low-prevalence antigen of the FORS 
blood group system [22] and it is considered one of the carbohydrate antigens  with the 
structure GalNAcα1→3GalNAcβ1→3Galα1→4Galβ1→4Glc→ceramide [23, 24]. 
 
Forssman antigen can be rapidly taken up or passively acquired by cells in medium 
containing serum from Forssman positive animals [25]. Chemically, Forssman antigen is 
distinguished from other antigens by their solubility in lipid solvents and stability to 
boiling, as it has a glycosphingolipid structure [26].  
 
The Forssman antigen has been previously found only in lower mammals, it present in 
various species but not in others, so they were categorized depending on the antigen 
expression [19]. Guinea pigs, horses, hamsters, sheep and chickens are Forssman-positive 
while ox, pigeon, rat and rabbit are Forssman- negative [19, 27]. It also has been found in 
some bacteria, such as dysentery bacilli and pneumococci [27]. 
 
It has been found with unequal distribution within the same tissue of the same species.  
Mainly it is expressed in tissues (as in guinea-pig, horse, cat, and dog ) [26, 28], on the 
erythrocytes (as in sheep), or in both (as in chicken) [29]. Thus, the rejection in 
transplantation by Forssman antibodies is depending on tissue expression of FORS 
antigen [19]. Svensson and her colleagues found that the FORS glycolipid is also 
expressed on human erythrocytes in a minority of individuals [12]. Thus individuals are 
grouped into FORS1 antigen negative individuals who produce the naturally occurring 
anti-FORS antibodies (most common) or FORS1 antigen positive individuals who do not 
produce the respective antibodies. 
  
6 
 
 
1.3 Biosynthesis of FORS Antigen 
 
In general, a blood group system consists of one or more antigens controlled at a single 
gene locus, or by two or more very closely linked homologous genes with little or no 
observable recombination between them [30]. 
 
Normally, human cells do not produce FORS glycolipid but produce its biosynthetic 
precursor [31]. Both Pk (a biosynthetic precursor of P) and P blood group antigens, 
known as globotriose (Gb3) and globotetraose (Gb4), respectively are precursors for 
Forssman glycolipid [32, 33]. All the antigens produced based on these precursors are 
glycosphingolipid (oligosaccharide linked to sphingolipid on the cell membrane) [34]. 
 
The biosynthesis of FORS antigen requires multiple glycan-processing enzymes. A 
terminal step - transfer of N-acetylgalactosamine (GalNAc) to the terminal GalNAc 
residue of globoside via an α1,3-linkage [13] - is catalyzed by GBGT1 gene product, 
Forssman synthetase [12, 19]. The GBGT1 gene was first isolated in canine kidney cell in 
1996 by using monoclonal antibodies against Forssman antigen [35] and three years later 
cloned in human [36]. GBGT1 is located on chromosome 9 (9q34) and consists of 347 
amino acids [6]. It is homologous to the alpha 1,3 GalNAc ABO A transferase (45% 
amino acid sequence identity) [6]. The human GBGT1 gene has also about 83% identical 
amino acids to the animal GBGT1 gene [14]. The whole gene consists of 7 exons 
spanning more than 8 kb of DNA  - of which the last one is the largest- with the coding 
region shared between all species positive for FORS 1 [12]. Figure1.2 represents 
Genomic organization of the human Forssman synthetase or GBTG1 gene, exon 1 
through exon 7. 
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Figure 1.2 Genomic organization of the human Forssman synthetase gene or GBTG1 gene. 
The seven exons are drawn to scale whereas the introns are not. The numerals above the boxes 
represent the number of nucleotides in each exon. Grey, vertical lines in exon 2 and 7 indicate the 
start and stop codons, respectively [37]. 
 
It is a GT6 enzyme (the glycosyltransferase gene family 6) and it also called Forssman 
glycolipid synthase (Fs) [12, 19]. GBGT1 mRNA expression has been observed in a 
variety of human tissues including small and large intestines, placenta, and ovary, but as 
a result of differential methylation, GBGT1 nonsense and inactivating missense 
mutations, a truncated or enzymatically inactive enzymes are produced [36].  
 
GBGT1 is also inactive due to point mutations or exon loss (cow, rat, primates) [13]. In 
all humans, the GBGT1 gene which can give rise to the Forssman antigen is present and 
mRNA has been found in several tissues in human, but an active enzyme is not observed 
[31]. A single point mutation in the GBGT1 gene makes the human Forssman synthase 
active and give rise to the blood group FORS, which was previously misclassified as an 
ABO subgroup.  The details of GBGT1 gene are summarized in Table 1.1. 
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Table 1.1   GBGT1 Gene Details.  
 
Gene symbol GBGT1 
Full nomenclature Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 
Designation Forssman glycolipid synthase (Fs) Forssman glycolipid synthase- like protein 
Protein family  GT6. Glycosyltransferase Family 6.  
Chromosome 9 ( 136028335 – 136039309) 
Map Location 9q34.13-q34.3 
Exon count 7 
Size 347 amino acids; 40127 Da  
Cofactor  Manganese   Mn++ 
Subcellular location Golgi apparatus membrane , Single-pass type II membrane protein 
Similar genes ABO*, GLT6D1*, A3GALT2*, and GGTA1P* 
Expression (Tissue 
specificity) 
Widely expressed, but usually expressed at higher levels in placenta, ovary and 
peripheral blood leukocyte. 
Function  Catalysis the terminal step of Forssman antigen biosynthesis: 
(transfer of GalNAc to the terminal GalNAc residue of globoside via an α1,3-linkage) 
First isolation date In canine kidney cell in 1996 and three years later cloned in human. 
 
*A3GALT2: Alpha 1,3-galactosyltranferase 2;  GLT6D1: Glycosyltransferase 6 Domain 
Containing protein 1; GGTA1P: glycoprotein, alpha-galactosyltransferase 1 pseudogene; ABO: 
transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-
galactosyltransferase. 
 
1.4   FORS1 antigen similarity with other blood group systems 
 
Forssman antigen has a glycosphingolipid structure which is composed of hydrophilic 
carbohydrates responsible for the antigenic specificity. They are also linked to the 
hydrophobic sphingolipid (ceramide) which is anchored in the outer leaflet of the 
membrane [38]. Forssman epitope, composed of 1 mole of glucose, 2 moles of galactose, 
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and 2 moles of acetylgalactosamine, is similar to blood group antigens and in contrast to 
that of globoside which contains a  less galactosamine (1 mole instead of 2 moles) [39]. 
Thus, Forssman antigen was shown to cross react with some blood antigens like A, para-
Forssman and PX2  [12]. In human, ABO transferase and Fs related genes have the same 
evolutionary origin [40] and the hypothesis that they arose by gene duplication and 
subsequent divergence supported by presence of both genes on the same chromosome 
9q34 [35].  
 
Immunologically FORS antigen  cross reacts with blood group A antigen as a result of 
presence of terminal non-reducing alpha linked N-acetyl D-galactoseamine residue in 
both [41]. It is interesting to note that, only those carbohydrate antigens which have a 
non-reducing terminal, such as Gal or GalNAc, and greater steric rigidity show strong 
antigenicity and thus have greater immunogenic clinical significance [39]. Forssman 
glycolipid is capable of inhibiting A-hemagglutination, and A-antigen inhibits hemolysis 
of sheep erythrocytes by anti-Forssman antibody [42]. FORS1-positive RBCs were 
agglutinated by polyclonal anti-A (3 of 18) and Anti-AB (8 of 18) but not with 
monoclonal anti-A and anti-B reagents [22, 43] .  
 
There is structural relatedness between FORS1 and blood group A antigens. The H 
antigen which is the natural precursor of A and the P antigen is also the natural precursor 
for FORS. A antigen is produced by addition of α3-N-acetylgalactosamine (GalNAc) 
residue by a 1-3 glycosidic linkage by A transferase (1,3-N-acetyl-
Dgalactosaminyltransferase) which catalyses the last step on the synthesis of A antigen to 
a precursor chain, H antigen. While, FORS antigen is produced by the addition of 
GalNAc to P (globoside) substance [4, 44]. Figure 1.3 shows the structure of H, A, P, 
and FORS antigens and their chemical composition. 
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Figure 1.3 H, A, P, and FORS antigens structure are schematically drawn showing their 
chemical composition. GalNAc and GlcNAc stand for N-acetylgalactosamine, N-
acetylglucosamine respectively.  When α3-GalNAc binds to the H-substance will give blood 
group A and when α3-GalNAc binds to the P antigen will give FORS antigen.  
 
The difference between GLOB and FORS blood group systems may be described as 
"what is common and what is rareʺ. In the GLOB system, the P antigen is common and 
anti-P antibody is very rare, whereas in the FORS system, the FORS1 antigen is 
extremely rare and most individuals are FORS negative and  naturally occurring 
antibodies are common [13]. 
 
1.5 Clinical Significance of Forssman Antigen 
 
There are no data about the influence of FORS antigen on human health because only 
few humans expressing the FORS1 antigen are currently known [13]. However, it may 
have as yet unknown biochemical functions. 
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 In general, previous studies suggested that variability in glycolipid synthesis between 
species is an important determinant of microbial tropism [31]. As we mentioned before, 
FORS antigen is one of globo series glycosphingolipid (GSL). GSL play roles in many 
biological processes. They associate with malignant diseases, angiogenesis, multidrug 
resistance, and serve as receptors for human pathogens [36]. In some species, the 
conversion of a Gb4 precursor into the FORS will have an impact on the adherence of 
pathogenic organisms, directly affecting microbial ecology and modifying host 
susceptibility to infectious diseases [45]. On the other hand, Gb4, the precursor of the 
FORS glycolipid, serves as an initial attachment site for bacteria, viruses, and toxins in 
humans and other species [31] and the adherence of microbes to host cells is the first step 
in colonization and pathogenesis process of most infectious diseases [46]. 
 
It is possible that FORS1 expression on human uroepithelial cells could make such 
individuals more susceptible to infection by E. coli (especially P-fimbrinated strains 
which enhance early bacterial colonization of the urinary tract [47, 48] that are believed 
to reflect microbial selection. Other organisms known to bind globoseries glycolipids 
including the Shiga toxins (Stx2e) and parvovirus B19, the causative agent of erythema 
infectiousum [31]. The Stx2e variant of Shiga toxin which causes piglet edema disease 
and responsible for hemolytic uremic syndrome has recently been shown to bind 
Forssman glycolipid, which makes this subtype unique among the Stx subtypes [49]. On 
the other hand, the expression of Forssman glycolipid protects host cells against some 
microbial diseases, they are less susceptible to the effect of Shiga toxin 1 (Stx1) [50], as 
FORS1 synthesis decreases the amount of Pk (a Shiga toxin (Stx) receptor) [13, 19, 51].  
FORS antigen like blood type A antigen have an essential role in the anti-depressive 
effects of glycolipids  in a mouse model of depression but the mechanism responsible for 
such a process is still unclear [52]. 
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1.6   FORS Antibodies; Indications and Clinical Significance 
 
Forssman antibodies (anti-Fs) are naturally occurring and arise against the missing 
antigen in plasma of humans who lack active GBGT1 gene [12]. They react strongly 
(agglutinate and hemolyze) with Forssman positive cells in human [12]. The majority of  
normal  human  sera  possessed anti-Fs with  hemolytic  activity  against sheep  
erythrocytes, whereas a  minority had  weak or undetectable  levels  of such antibodies 
[53]. The incidence of FORS antibodies is more than 75% in random healthy individuals 
[54], whereas in cancer patients is only 35–40% [55]. Most of them belong to the IgM 
and some IgG classes and usually reactive at 37°C [13, 56].  
 
The level of anti- Fs titer is influenced by age and the titer decreases gradually with 
advancing  age in normal individuals [53]. By sex, the titer is higher in females than male 
patients and by blood group, the titer is higher in blood group AB than other blood 
groups. Although one study indicated that FORS  antibodies  in  sera  is  independent  of 
blood  group [53]. In addition, anti-Fs antibody production is influenced in cancer 
patients by the histologic type of cancer, the titer is lower in differentiated 
adenocarcinoma and by the stage of the disease. The Anti-Fs titer also showed variations 
in both Igs classes, IgG and IgM [57].  
 
The clinical significant of anti-Fs is unknown.  It could be considered as one of the 
heterophilic antibody barriers in clinical organ transplantation [38, 58]. Many years ago, 
scientific researchers studied the relationship between complement-dependent hemolytic 
activity and the amount of the Forssman antisera hemolysin by measuring the lesion on 
the surface of a sheep erythrocyte, IgM was more effective [59]. 
 
The activity of FORS immunoglobulins were measured by haemolysis and cytolysis. For 
IgG antibodies were similar, but the IgM were showed to have much greater activity by 
haemolysis than by cytolysis compared to IgG antibodies, because it is more efficient 
than IgG antibody in activating complement due to its ability to place several Fc 
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(fragment crystallizable) receptor sites in close proximity [60]. Thus the IgM anti-FORS 
antibody is inefficient in lysing nucleated cells [61].  
 
 The anti-Fs present in sera may bind complement and could possibly cause intravascular 
lysis of transfused Fs-positive RBCs [12, 62].  So, these antibodies might have 
implications in transfusion medicine, organ transplantation and during pregnancy [12]. 
Furthermore, FORS antibodies could be - like most of naturally occurring anti 
carbohydrate antibodies - implicated in hemolytic disease of the fetus and newborn 
(HDFN) [13, 63]. The severity of graft rejection due to FORS antibodies may diminish 
when the levels of such antibodies are decreased by mechanisms of adaptation like 
immunosuppression, neutralization, or absorption of antibodies and plasmapheresis [38]. 
 
Anti-Fs antibodies have the ability to disrupt tight junction formation, cell adhesion, and 
apical-basal polarization, suggesting that glycosphingolipid molecule may participate in 
recognition and communication processes [64-66]. They may also function as anti-tumor 
antibodies [67]. As we mentioned before, their titer in patients with colonic and lung 
cancers would be low compared with healthy individuals.  This decrease in Forssman 
antibodies titer in cancer patients was ascribed to the anti-Fs-Fs immune complexes when 
Fs antigen will be shed from the tumor and absorbed by anti-Fs as "self-non-self' cancer 
concept. The antigen-antibody complexes are then removed from the circulation by 
phagocytes [53, 68]. In addition, it  may be  the result  of a  number  of  factors,  
including  nonspecific effects such as  debilitation (tiredness or loss of energy)  and  
immunosuppression. [53].  Thus, serum level of Forssman antibodies could be used 
clinically, as an index to determine the cancer recurrence in post-surgically cancer 
patients [57]. It was also noted a decrease in the level of heterophilic Forssman antibodies 
in the sera of females with malignant and benign genital tumors compared with healthy 
ones [69]. 
 
Fs antibodies also can be used to diagnose infectious mononucleosis (IM), a disease 
caused by the Epstein-Barr virus (EBV), both have activity against Forssman antigen 
[70]. The Davidsohn Differential Test was used to differentiate between heterophile 
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sheep cell agglutinins in human serum due to Forssman antigen, serum sickness, and 
Infectious Mononucleosis [71] (Table 1.2).  
 
 
Table 1.2.  Davidsohn differential test for differentiation between IM, anti-Fs and Serum 
Sickness  
Antibody  Absorbed by GPK* Absorbed by BBC* 
 
Infectious Mono antibody 
 
NOT absorbed 
 
Antibody removed 
 
Forssman antibody 
 
Antibody removed 
 
NOT absorbed 
 
Serum Sickness 
 
Antibody removed 
 
Antibody removed 
         *GPK: guinea pig kidney and BBC: boiled beef cell. 
 
Donath-Landsteiner autoantibodies that cause paroxysmal cold hemoglobinuria (PCH) 
syndrome are also  inhibited by Forssman glycolipid more effectively than by globoside 
[70]. High Fs autoantibody titers were also found in Graves' disease and Hashimoto's 
thyroiditis [36, 72]. These results suggest that anti-Forssman antibody may be involved in 
the pathogenesis of these autoimmune diseases [72]. In contrary, low Fs antibodies were 
found in sera of patients with Guillain-Barré syndrome (GBS) [73]. 
 
Fs antibodies were also used as a new biomarker and early indicator for postvaccination 
immune responses in poxvirus-based prostate cancer vaccine. The vaccine was designed 
to stimulate T-cell responses to prostate-specific antigen (PSA) by comparing serum 
antiglycan IgG, IgM, and total Ig profiles in patients before and after initiating treatment 
with PROSTVAC-VF [74]. Figure 1.4 summarize the advantages and disadvantages 
according to Forssman antibodies and antigen.  
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Figure 1.4. Summary of the advantages and disadvantages of Forssman antigen and 
antibodies. PCH; paroxysmal cold hemoglobinuria, HDFN; hemolytic disease of the fetus and 
newborn, StX1: Shiga toxins, Stx2e; Shiga toxin 2e, Fsdi; is used as an indicator for disaccharide 
of the FORS antigen (Fsdi=GalNAcα1-3GalNAcβ), PSA; prostate-specific antigen.  
 
1.7   Detection of FORS Antigen and Antibodies 
 
There is no routine diagnostic serologic reagent being used to detect this red blood cell 
phenotype, although Forssman reagents are available [43]. All blood groups antigens can 
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be detected serologically by reacting RBCs with specific antibodies that are prepared 
specifically against those blood groups’ antigens [75].  
Currently, direct crossmatching, lectin screening or DNA screening for 887G>A are used 
to detect Fs-positive donors [12]. RBCs expressing FORS1 antigen are agglutinated 
strongly by Helix pomatia lectin (HPL), a lectin from Helix pomatia agglutinin [76]. The 
lectin reacts with both Fsdi-kodecytes and FORS1-kodecytes but it slight preferentially 
binds Fsdi (GalNAcα1-3GalNAc-R), the terminal disaccharide of Fs antigen over the 
pentasaccharide [43, 77]. It recognizes (αGalNAc) containing epitopes which are present 
in cancer cell lines in the very early stages of the metastatic process. HPA staining was 
used and served as a “surrogate marker” for Fs antigen expression [36]. So, elevated HPA 
staining in the tissues could be a result of the increased GBGT1 expression and Fs 
synthesis. Thus, it is a determinant for poor prognosis in some carcinomas and 
malignancies, if GBGT1 gene expression increased in those tissues [36, 76]. 
 
In the past, sheep erythrocytes were used to detect FORS antibodies as they contain great 
amounts of the Forssman antigen. Recently, Kodecytes with synthetic disaccharide (Fsdi 
–kodecytes) and pentasaccharide Forssman (FORS1-kodecytes,) function-spacer-lipid 
(FSL) constructs were used to detect the anti-FORS [43]. The FSL-FORS1 is synthesized 
to be similar to the natural glycolipid of Forssman with some differences.  
 
	1.8   Mechanisms for FORS Antigen Positivity and Negativity in Human 
 
 There have been studies aimed to understand why human tissues do not express 
Forssman glycolipid. The absence of Forssman glycolipid (FG) in normal human tissues 
indicates either that this molecule is dispensable in terms of physiological functions [35] 
or there is another glycolipid that has the same function as FG [31]. Previous studies 
showed that the human FS mRNA was translated less efficiently than other species. Thus, 
protein synthesis was absent rather than the absence of functional Fs enzyme. 
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Some studies have reported the presence of the FORS antigen in certain human 
embryonic tissues [45]. Small amounts of FORS antigen were also found in some 
specimens of normal human gastric and colonic epithelium and in gastric [42, 53], 
colonic, and pulmonary carcinomas from cells originated from Forssman negative tissues 
[56, 66, 67]. The Forssman pentaglycosylceramide has also been characterized in normal 
human kidney [78] and in human lung [79]. 
 
Many mechanisms were hypothesised and contributed in GBGT1 gene changes and thus 
reactivate Forssman synthase in humans, but they are extremely rare [74]. Those 
mechanisms include overexpression of the GBGT1 gene mRNA, which might acquire 
altered enzyme specificity, increased stability of mRNA and protein, splicing variations, 
aberrant glycosylation by another GT, and post-translational protein modifications [19].  
 
Recently, the basis of the Forssman antigen negativity in humans was clarified. Two 
inactivating missense mutations were identified and produced a truncated or 
enzymatically inactive enzyme and are very common in almost all individuals. A 
c.887G.A [p.Arg296Gln] polymorphism confers Forssman antigen positivity in the Apae 
individuals, and Yamamoto suggested that either this or c.688A.G [p.Ser230Gly] 
polymorphism alone in human may produce GBGT1 gene protein with weak Fs activity 
[19]. The presence of FORS1 on erythrocytes in the Apae individuals may be produced by 
those cells or adsorbed from tissues like the Lewis antigens [19]. 
 
Thus, Gln296 is responsible for activating Fs and present in lower mammals, whereas 
Arg296 is responsible of inactivating Fs (wild type) and found in primates, including 
humans [12, 22]. The explanation of that, the exchange of arginine by glutamine 
permitted the enzyme to make contact with the UDP- sugar (uracil-diphosphate-sugar) 
donor then catalyses synthesis of the terminal 3-a-N-acetylgalactosamine to its globoside 
acceptor [37, 80]. 
 
 
18 
 
1.9   FORS Antigen & Cancer 
 
In general, the change in the antigen expression is not constant, it could undergo 
variations during cellular differentiation, development, and aging as well as pathologic 
conditions, mostly in carcinogenesis [81]. Several reports have described the presence of 
blood group antigens in tumor tissues. The appearance of incompatible blood group 
antigens foreign to the host may occur in some human tumors as a result of functional 
and morphological differentiation of the cell [42, 82]. 
 
In the past, Forssman antigen was only detected in malignant tissues- but not detectable 
in the adjacent normal tissue although contained its globoside precursor substance- 
including gastric, biliary adenocarcinoma in liver, cervical cancer [83], colonic mucosa 
and lung carcinoma [84]. It was detected in tumors derived from Forssman-negative 
tissues whereas in Forssman-positive individuals this antigen was lost if tumors develop 
[12, 53].  On the other hand, some human tissues neither the normal nor malignant did 
not contain the Forssman antigen such as breast tissues [85], although a recent study 
reported the presence of FORS1 in breast cancer tissues [76]. Thus, the appearance of 
Forssman antigen in tissues is not associated with conversion of normal cells into tumor 
cells [85] but it has implication in cell adhesion, migration, proliferation and tumour 
growth [86].   
 
In human, the mechanism of how Forssman antigen emerge in some tumors and 
malignancies is unknown. Some factors related to tumors may be reactivation of 
Forssman synthase, or other N-acetylgalactosaminyltransferases may be activated and 
lose their substrate specificity and thus may synthesize Forssman antigen [35]. Certain 
tumor tissues exhibit higher concentration of UDP-GalNAc (uracil-diphosphate- N-
acetylgalactosamine) and Gal-GlcNAc (Galactose-N-acetylglucosamine) than threshold 
levels in the Golgi apparatus. Thus, the O-GlcNAc tranferase (OGT) will be activated 
and O-GlcNAcylation of target protein enhanced [19] or tumor induction of other 
enzymes having a similar GBGT1 enzymatic activity [28]. 
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GBGT1 is one of glycosyltransferase-encoding genes that is regulated by DNA 
methylation. Previous studies explained one mechanism by which GBGT1 expression is 
regulated on the transcriptional level in ovarian cancer. They showed  that GBGT1 
expression is silenced through DNA hypermethylation in ovarian cancer cells but was re-
activated by 5-Aza (5-Azacytidine) treatment [36].  
 
As we mentioned before, the FORS1 antigen expression has been shown in many types 
of malignancy and carcinomas, so it could be recognized as a tumor-associated antigen 
[42]. The anti-Fs lectin (Helix pomatia) was used to recognize αGalNAC containing 
epitopes and the tumor tissues exhibiting higher concentrations of UDP-GalNAc and 
UDP-GlcNAc, which showed increased level of OGT [19]. So the detection of αGalNAc 
epitopes in cancer cell lines in the early stages of the metastatic process can be used as a 
tumor marker and used to follow treatment and disease prognosis. In addition, it might be 
possible immunologically to suppress tumors in O or B individuals by immunization with 
FORS glycolipid suitably arranged on a carrier macromolecule [42].  
 
All these results confirming unusual enhancement of activity of FORS antigen in human 
tissues was strongly related to carcinogenesis and indicated that assay of the antigen 
would be of value to detect cancer [87]. Since the Forssman antigen is a tumor-specific 
antigen, it could be possible to incorporate it into conjugated vaccines used to target 
different types of cancer to raise an immune response against the Forssman 
pentasaccharide expressed on the surface of such cancerus cells [88]. 
 
Herein, we investigate the prevalence of FORS1 antigen in  a Palestinian donors and a 
smaller European donors from Sweden and Portugal. We also aimed to determine the 
molecular basis for Forssman antigen negativity in those populations and to develop a 
method for routine testing of donor blood for the anti-Fs antibodies. 
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1.10   Problem Statement 
 
The expression of FORS1 antigen has been demonstrated in several human tumors and 
FORS1 antibodies might have implications in both transfusion medicine and organ 
transplantation. The negativity of FORS1 antigen in humans has also been recently found 
to be due to two missense mutations in the GBTG1 gene.  The global frequency of the 
FORS  blood group is still  unknown. The frequency of FORS1 antigen is probably very 
low and thus, most  individuals are genetically FORS1 antigen negative. There are no 
previous studies about the prevalence of antigen and antibodies of Forssman in general, 
and its molecular basis neither in Palestine, nor in some other populations. 
 
Recently in Sweden, Lund University has screened 256 blood donor for the c.A887G 
(Gln296Arg) and all of them were mutant [12, 37].  In general, the present study aimed to 
contribute to a better understanding of the Forssman antigen and antibodies in healthy 
individuals in the selected populations, the subject of this study. 
 
1.11   Study Aims  
 
The general aim of this study was to investigate the FORS blood group antigen (FORS1) 
and antibody (anti-FORS1) in specific populations (Palestine, Sweden and Portugal) and 
to determine the molecular basis of Forssman antigen negativity in these populations. 
 
The specific aims were : 
 
 To study the prevalence of Forssman Antigen in Palestinian population and some 
European populations in Sweden and Portugal. 
 To validate the presence of anti-FORS by developing a method for routine testing 
of blood donors.  
 To investigate the genetic mutations responsible for FORS1 antigen negativity in 
those populations. 
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Chapter Two  
 
 
Materials and Methods 
2.1 Materials  
 
All materials used in this study are listed in Table 2.1. All reagents and chemicals used 
were of analytical grade. 
 
Table 2.1. Instruments and reagents used in the study.   
 
 
Item 
 
Components 
 
Supplier/Company 
 
Blood collection tubes 
 
EDTA Vacutainer® blood tubes. 
 
 
Blood grouping reagent 
 
Commercial sera: Anti-A, anti-B 
and anti-D 
 
 
Fixative solution 
 
Formaldehyde 
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MasterPure™ DNA 
Purification Kit for Blood 
Version II 
1- Red Cell Lysis Solution
   
2-Tissue and Cell Lysis Solution  
3-MPC Protein Precipitation 
Reagent     
4-RNase  
5-TE Buffer (10 mM Tris-HCl [pH 
7.5], 1 mM EDTA) 
 
Epicentre Chicago, 
USA. 
PCR machine 
 
DNA Engine PTC-200 Peltier 
Thermal Cycler (Dual-Block 
Models) 
SDS (Scandinavian 
Diagnostic Services) 
Carlsbad, USA 
PCR tubes 0.5 ml thin-walled reaction tubes 
with flat caps, Lot. AB-0533. 
Thermo Scientific 
Waltham, USA 
PCR components  Colorless Master Mix 1.1 X Thermo Scientific 
Waltham, USA 
GeneJET PCR purification 
kit  
Binding Buffer, concentrated Wash 
Buffer, Elution Buffer (10 mM 
Tris-HCl, pH 8.5) and GeneJET 
Purification Columns 
(preassembled with collection 
tubes). 
Thermo Scientific, 
Waltham, USA 
ABI PRISM® 310 Genetic 
Analyzer 
10x EDTA buffer, Polymerase  Applied Biosystems, 
California, USA 
Cycle sequencing kit BigDye® Terminator v1.1 
Sequencing kit ( BigDye 
Terminator v1.1 Matrix Standards) 
Applied Biosystems, 
California, USA 
Injection solvent for genetic 
analyzer  
Hi-Di™ Formamide Applied Biosystems 
(PN 4311320) 
Agarose LE EEO 0.12 PRONAROSE 
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Nucleic Acid Gel Stain GelStar Lonza, Basel, 
Switzerland 
PCR product Dye 1- 6x Loading Dye Solution 
2-BFB-glycerol 
 
Gel agarose standard Gel agarose standard O GeneRuler 
100 bp (green color). 
Fermentas, 
Waltham, 
Massachusetts, USA. 
Power Supplier E443 ( 100-150 voltage) CONSORT, 
Hertfordshire, 
England. 
RBC 
Preservative/stabilization  
solution 
CellStap Bio rad, Hercules, 
California, USA. 
Precipitation solution for 
anti-FORS1. 
Ammonium sulfate  
(C=0.18 g/ml) 
 
Gel cards 1-NaCl, Enzyme Test & Cold 
agglutinins for IgM. 
2-Coombs Anti IgG (rabbit) for 
IgG. 
 DiaMed, GmbH, 
Cressier FR, 
Switzerland)  
PBS Buffered isoton NaCl (pH=7.1)  
Gel card centrifuge ID- Centrifuge 12 SII 
Micro Typing System 
DiaMed-ID 
Gel card incubator ID-Incubator 37C DiaMed, Ghaziabad, 
India. 
Secondary antibodies  Fluorescein isothiocyanate (FITC) 
goat anti-mouse IgG (H+L, Heavy 
and Light chains) and IgM 
secondary antibodies. 
Zemed, Invitrogen, 
Carlsbad, CA) 
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Penta-kodecyte FSL (Function Spacer Lipid) 
construct 
20 µg/mL penta Fs solution 
(KODE technology, 
Auckland, New 
Zealand;http://www.
kodebiotech.com). 
Anti-Fs culture supernatant  monoclonal anti-Fs IgM which was 
concentrated from hybridoma tissue 
culture supernatant, rat cell culture 
(M1/22.25.8.HL 
(ATCC® TIB. 121™) 
ATCC, Manassas, 
Virginia. 
HPA (Helix pomatia 
agglutinin) 
Lectin from Helix pomatia SIGMA –
ALDRICH, USA 
 
 
2.2 Methods 
 
2.2.1   Study Population  
 
A convenient sample of 211 Paletinian adults, aged 19- 35 years ( mean 20.5 ± 2.5 SD) 
who were students at Al-Quds University,  main campus in Abu Dies were recruited to 
participate in this study. Study donors were from different geographical cities in Palestine 
(Figure 2.1) and from different colleges (Figure 2.2). The details of each Palestinian 
donor are present in Appendix B and sample collection method in Palestine is present in 
appendix C. 
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Figure 2.1. Regional distribution of Palestinian participants. Data are expressed as percentage 
(%). 
  
 
 
 
Figure 2.2. Distribution of Palestinian donors based on the faculty they were attending at 
time of sampling. Data are expressed as percentage (%). 
26 
 
Additionally,  DNA samples from 47 Swedish and 18 Portugease blood donors as the 
Euoropean population were included in the study. All Swedish  DNA samples were from 
randomly picked blood group O donors, thus the age or gender of them were unknown. 
Portuguese donors baseline characteristics are summarized in Table 2.2.   
 
 
Table 2.2. Portuguese donors (n=18) baseline characteristics. Results are expressed as mean ± 
SD for age variable, and as frequency for the gender and blood group. 
 
 
 
Gender 
 
M: 9         F: 9 
 
Age 
 
Mean= 28.5   SD ±12.96 
 
Blood group  
 
Unknown 1 
A Rh-       1          A Rh+     5 
AB Rh-    0         AB Rh+    2 
B Rh-       1           B Rh+     1 
O Rh-       3           O Rh+    4 
 
 
2.2.2  Study Questionnaire 
 
An interview-based questionnaire was prepared for this study and aimed to collect 
general demographic data (gender, age, college, residence place [city)]) and general 
health status. A copy of the study questionnaire is shown in Appendix D (study 
questionnaire in Arabic and English languages). 
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2.2.3 Sample Collection and Preparation 
 
Subjects who accepted to participate in the study were asked to donate 5 ml of blood. 
Blood samples were collected using a syringe and dispensed  into two EDTA tubes. One 
for blood typing and preparation of buffy coat for genomic DNA purification and the 
second tube for antibody testing. Blood samples were centrifuged at 3000 rpm for 5 
minutes in a Heraeus Labofuge (model 200, UK) and the following components were 
collected: 
- From the tube intended for blood typing and DNA preparation, the buffy coat 
(200 µL) was transferred to a new tube, stored at -20°C and used for preparation 
of genomic DNA as described in a later section; RBCs were collected, stored 4-
8°C and used later for blood typing.  
- From the tube intended for antibody testing, plasma was collected and stored at -
20°C until used. 
 
 
2.2.4    Ethical considerations 
 
 All subjects who agreed to participate in the study were briefed about the study aims and 
asked to sign an informed consent (See the study questionnaire in Appendix D). The 
principles of Helsinki declaration for scientific research  were applied. 
 
2.2.5    ABO Grouping and Rh Typing 
 
ABO grouping and Rh typing were done by standard tube method. A small quantity of 
whole blood was washed 3 times by normal saline. Three drops of RBC deposit were 
suspended in 5 mL of normal saline to give 3-5% suspension of red cells. Three tubes 
labelled A, B and D were used for grouping as shown in Table 2.3.  The tubes were 
mixed briefly and let to stand for 10 minutes at room temperature. Tubes were then 
centrifuged for 1 minute at low speed, 1000 rounds per minute (rpm) by using Heraeus 
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Labofuge 200,UK. The tubes were mixed, and the deposits of red cells were examined 
for agglutination. Agglutination of tested RBCs indicated a positive result or presence of 
the respective antigen. While lack of agglutination of tested RBCs indicated a negative 
result or absence of the respective antigen.  
 
Table 2.3.  ABO standard tube procedure. 
       Tube A Tube B Tube D 
Anti-serum One drop 
(Anti-A ) 
One drop 
(Anti-B ) 
One drop 
(Anti-D ) 
3% red cell suspension One drop One drop One drop 
 
2.2.6   FORS1 antigen typing: 
 
 Grouping for FORS antigen was performed using monoclonal anti-Fs IgM which was 
concentrated from a hybridoma cell culture supernatant, rat cell culture (M1/22.25.8.HL 
(ATCC® TIB. 121™). A small quantity of whole blood was washed 3 times by normal 
saline. An equal volume from 3% suspension of washed RBCs and anti-Fs were added in 
a tube and incubated for 1 hr at room temperature. The tubes were then centrifuged for 1 
minute at low speed (1000 rpm) by using Heraeus Labofuge 200,UK. They were graded 
macroscopically according to standard blood bank practice and the result was interpreted 
as described for the ABO typing method. Some samples were picked and examined 
microscopically to verify the negative reaction. 
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2.2.7   FORS Antibodies 
 
In the absence of natural FORS1-positive RBCs, more than one method were tested for 
anti-Fs antibodies detection. Then, sheep red blood cells protocol (2.2.7.4) was used to 
test plasma from study subjects. 
 
2.2.7.1    Ammonium sulfate precipitation for FORS1 antibodies 
 
A suspension of Forssman antibodies was obtained from the respective cell culture. The 
cells used in this culture were derived from early mouse embryo, hybridoma B 
lymphocytes and rat IgM isotype. The suspension was concentrated by ammonium 
sulfate precipitation.  A solution of 0.18 g/ml ammonium sulfate was prepared by diluting 
9 g of ammonium sulfate in 50 ml of distilled water. An equal volume of ammonium 
sulfate was added slowly to antibody supernatant to give a final concentration of 50% 
saturation. The cells were incubated at 4°C for 2 hrs and then centrifuged  at 3000 rpm 
for 10 minutes in a Thermo Scientific Multifuge 1S-R, Woburn, MA. The supernatant 
was removed and the pellet was suspended in phosphate-buffered saline (PBS) to give 
10%-20% of the starting volume. 
 
2.2.7.2    Kodecyte- based serological test for FORS1 antibodies 
 
For penta Kodecyte preparation, the synthetic glycolipids were adsorbed onto blood 
group O RBCs which are then called Kodecytes and used for testing plasma for anti-
FORS1 antibodies. Briefly, FSL (Function Spacer Lipid) construct for FORS1 
pentasaccaride was obtained from KODE Biotech Materials Ltd (KODE technology, 
Auckland, New Zealand;http://www.kodebiotech.com). Blood group O RBCs were 
washed 6 times with PBS buffer. In every washing step, RBCs were suspended in at 
plenty of PBS buffer, centrifuged at 3000 rpm for 5 minutes and supernatant was 
discarded. The latter process was repeated 6 times and RBC pellet was suspended in PBS 
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to give an RBC suspension with a PCV of about 80%.   Next, 100 µL of 100µg/mL penta 
Forssman FS- FSL solution were diluted by PBS buffer to make a concentration of 
25µg/mL.  A 100 µL of the washed group O RBC were added to 200 µl of the 25µg/mL 
modification solution (1:3). The solution was then incubated at 37°C for 2 hrs with 
occasional mixing and then cell suspension was incubated at 4°C overnight. After that, 
the treated RBCs were washed 6 times with PBS buffer and re-suspended in RBC 
preservative (CellStab) solution to 0.8%. Also, untreated O RBC was prepared with RBC 
preservative (CellStab) and used as a negative control. Treated cells (synthetic 
glycolipids adsorbed onto RBC, Kodecytes) and untreated RBC were tested using Gel 
cards and Flow cytometry methods. 
Additionally, a second preparation of Kodecytes was prepared by incubating O cells in 50 
µg/ml of FS-FSL solution instead of 25 µg/mL and then suspended in CellStab to give a 
1% suspension of kodecyets. The second preparation of kodecytes aimed to investigate 
the effect of FS-FSL concentration in preparation of kodecytes. The kodecytes were 
tested by two methods:   
Penta Kodecyte gel card method: The Kodecytes were tested in two gel cards; NaCl 
and cold agglutinins (DiaMed) for IgM and Coombs Anti IgG, rabbit (DiaMed) for IgG. 
As a positive control, a 50 µL of treated RBCs (Kodecytes) were crossed with 25µL of 
1:100 Helix pomatia lectin and anti-Fs culture. As a negative control, CellStab, Apae W 
plasma, and Apae B plasma were used (two FORS1 positive individuals). The same steps 
were done by untreated RBCs as a negative control. The cards were incubated at room 
temperature for 15 minutes for IgM and at 37°C for IgG using ID-Incubator (DiaMed, 
Cressier FR, Switzerland). Then, gel cards were centrifuged at 1030 rpm for 10 minutes 
using ID- Centrifuge 12 SII Micro Typing System (DiaMed-ID, Cressier FR, 
Switzerland). Gel cards were then examined visually and interpreted according to the 
manufacturer’s directions. 
Penta Kodecyte Flow Cytometry method:  For RBC fixation, a 50 µL of RBCs (treated 
and untreated) were fixed by the addition of 100 µL of paraformaldehyde to reduce 
agglutination of antigen-positive cells. The cells were then incubated at room temperature 
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for 20 minutes under constant mixing. Cells were centrifuged at 300 x g for 1 min and the 
supernatant was discarded. The fixed RBCs were used in the flow cytometry method. 
 
As primary antibody, a 25 µL and 20 µL of anti-Forssman and plasma from Apae W and 
Apae B, respectively were added to fixed RBCs. As a negative control, 25 µL of PBS 
buffer was used. PBS was added to a total volume of 50 µL to each tube. Tubes were 
incubated at room temperature for 10 minutes under constant mixing. After that,  
incubation continued at  at 4°C for an additional 50 minutes. The cells were washed twice 
with 150 µL PBS.  The RBC pellet was re-suspended in 50 µL PBS. A 5 µL from FITC- 
goat anti-mouse IgG (H+L) and IgM (Zemed, Inviitrogen, Carlsbad,CA) secondary 
antibodies were added. After incubation at room temperature for 10 minutes in the dark 
under constant mixing, the samples were washed twice with 150 µL PBS. Then, the 
RBCs were re-suspended in 300 µL PBS. The results were analysed by BD FACSCalibur 
Flow Cytometry System using FACSflow sheath fluid. In total, 10,000 events were 
collected at a flow rate of 60 µL/min. 
 
2.2.7.3    Using 50µg/ml FSL-Fs pent saccharides with diluted plasma- Gel card 
method 
 
Different dilutions of plasma titres were prepared, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 
and 1:256 for Apae W, Apae B, and random sample (it was negative for FORS1 antigen). 
The protocol in part 2.2.7.2 was done except that the 0.8% kodecytes were replaced with 
the 1% kodecytes. 
  
2.2.7.4   Using sheep red blood cells 
 
Sheep RBCs –as Forssman antigen source- were washed 4 times with PBS buffer and 
suspended in Low Ionic Strength Solution (LISS) to a final concentration of 0.8%. For 
sheep RBCs treatment, bromelain (Br) enzyme was used to remove antigens that mask 
the FORS1 antigen. Sheep RBC were incubated with bromelain  at room temperature for 
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10 minutes..  Additionally, sheep RBCs were treated with bromelain without washing to 
look their reaction. The cells were then tested with plasma from  Apae W and Apae B 
individuals as well as with anti-Fs antibodies (IgM obtained from cell culture 
supernatant). A serial dilution of plasma titres, 1:2, 1:4, 1:8, 1:16, 1:32 and 1:64 also 
were performed and tested with sheep RBCs by gel cards.  
 
For tube method, sheep RBCs were washed four times with PBS and suspended in PBS 
to give a 0.8% suspension. Two drops of plasma sample were mixed with 1 drop of 0.8% 
suspension of sheep RBC. The tubes were incubated for 1 hr at room temperature (for 
saline testing) and at 37°C (for AHG testing). Each sample was also tested in duplicate 
and tested in saline to assess IgM agglutinins and with AHG for testing for IgG 
agglutinins. 
 
For  Gel card method, a 50μL of 0.8% suspension of sheep RBCs were transferred into 
each of two gel cards (Bio Med): the first card contained NaCl, Enzyme & Cold 
agglutinins for IgM and  the second card contained rabbit anti-human IgG (AHG 
reagent). A 25 μL of each plasma sample were added to each gel card. The cards were 
incubated for 15 minutes at room temperature for first card (saline and enzyme card) or at 
37°C (for the AHG card).  Then, gel cards were centrifuged at 1030 rpm for 10 minutes 
at 900/1000 rpm using ID- Centrifuge 12 SII Micro Typing System (DiaMed-ID, Cressier 
FR, Switzerland). Gel cards were then examined visually and interpreted according to the 
manufacturer’s directions. 
 
 2.2.8   DNA Analysis   
 
Our aim in this part was to sequence and analyse the exon 7 of GBGT1 gene and more 
specifically the 3’ end of exon where most gene-inactivating mutations occur such as 
c.688G.A [p.Gly230Ser] and c.887A.G [p.Gln296Arg mutations. Preparation of Genomic 
DNA was performed from buffy coat which was collected from 2 ml of EDTA whole 
blood and used for the DNA purification processes.  
33 
 
2.2.8.1    Preparation of genomic DNA 
  
For Palestinian samples: Genomic DNA was prepared from buffy coat using the 
MasterPure™ DNA Purification (Epicentre) according to the manufacture instructions for 
Blood Version II kit. Briefly, a 2 ml EDTA whole blood was centrifuged at 1,000 x g for 
15 minutes. A 200 μl of buffy coat (the white interface between the plasma and the red 
blood cells) was transferred carefully to a new tube. The buffy coat was either processed 
immediately or stored at 4°C for 1-7 days. The buffy coat sample was vortexed and was 
transferred to 1.5 ml micro centrifuge tube. A 600 μl of Red Cell Lysis Solution was 
added. The tube was inverted three times and then the bottom of the tube was flicked to 
suspend any remaining material. Then, it was incubated at room temperature for 5 
minutes, inverted three times and it was flicked as outlined above. Then, it was incubated 
at room temperature for an additional 5 minutes, inverted three times and then it was 
flicked. The white blood cells were pelleted by centrifugation for 25 seconds. The 
supernatant was removed and ~25 μl of liquid was left. The tube was vortexed to suspend 
the pellet. The white blood cells were re-suspended in 300 μl of Tissue and Cell Lysis 
Solution by pipetting several times. A 1 μl of RNase was added and was mixed 
thoroughly, and then it was incubated at 37°C for 30 minutes. The samples were placed 
on ice for 3-5 minutes. A 175 μl of MPC (MasterPure™ Complete) Protein Precipitation 
Reagent was added to 300 μl of lysed sample and vortexed vigorously for 10 seconds. 
The debris was pelleted by centrifugation for 10 minutes at 13 rpm. The supernatant was 
transferred to a clean centrifuge tube and the pellet was discarded.  A 500 μl of 
isopropanol was added to the recovered supernatant and mixed by inverting the tube 30-
40 times. The DNA was pelleted by centrifugation at 4°C for 10 minutes in a 
microcentrifuge. The isopropanol was poured off carefully without dislodging the DNA 
pellet. Then, the pellet was rinsed twice with 70% ethanol. All of the residual ethanol was 
removed. The DNA was re-suspended in 35 μl of TE Buffer. The extracted DNA was 
stored at –20°C.  
For Swedish samples, genomic DNA was prepared using Qiagen EZ1 DNA Blood 200 
μl Kit (Robot) for automated purification of genomic DNA from whole blood samples. 
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Procedure details are provided in Appendix E. The BioRobot EZ1 DSP system (Qiagen, 
Germany) is a fully automated machine and uses magnetic-particle technology.  
For Portuguese samples, genomic DNA was prepared using Wizard Genomic DNA 
Purification Kit (Promega). The procedure details are provided in Appendix F. 
 
2.2.8.2   DNA Quantification 
 
DNA concentration for Palestinian samples was measured spectrophotometrically by 
(Nanodrop 2000c; Thermoscientific) and for Swedish samples, the BioPhotometer 
Plus (Eppendorf) was used. Distilled water was used as a blank. Most readings were done 
twice to check the accuracy and precision. Spectral measurements at 230nm, 260nm, and 
280nm were also done and the ratios (260/280 nm and 260/230 nm) were calculated to 
assess the purity of DNA samples. DNA concentration was adjusted to 50-150 ng/μL) in 
each 25 μL PCR reaction. Concentrated DNA samples were diluted with TE buffer. In 
contrary, the volume of template DNA was increased for samples with low concentration. 
DNA samples with good purity and A260/A280 ratio about 1.8 (1.7 to 1.9) were used.  
 
2.2.8.3 Primer Design 
 
We planned initially to sequence the whole GBGT1 gene. So, five pairs of primers were 
designed covering exons (2-7) using the primer design software in UCSC database from 
University of California, Santa Cruz Genome Bioinformatics. The sequence, length, 
melting temperature, nucleotide position and sequence are listed in Table 2.4. Our 
primers were 18-22 bases in length. They were selected with an average GC content 
around 52.4%-66.7% with random base distribution. Because exon 7 is long and it has 
high GC content, three primer pairs A, B and C were used and designed to cover the 
whole exon 7.  Exon 7C primers were designed and used for all the samples. It covers 
from 970-1361 nucleotide (395bp) positions in mRNA according to EMBL (the 
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European Molecular Biology Laboratory) accession no. ENST00000372040 (position of 
220-347 amino acids) which include the main SNPs reported to cause inactivation of the 
enzyme (namely Gln296Arg & Gly230Ser). 
 
Table 2.4.  Primers used for analysis of GBGT1 gene.  
   P
rim
er  
 
Oligo1 Name 
 
Sequence (5’->3’) 
 
Length 
(bp) 
 
Tm
2
  
 
GC- 
content 
1 Exon 2 F3 CTCAGAGCCTGACATCCCTG 20 61.4 60% 
2 Exon 2 R4 AGTCCTGGGTGGGGATAGAG 20 61.4 60% 
3 Exon 3 F GTTTTCAGCCTCTGGTGCAG 20 59.4 55% 
4 Exon 3 R CTCTCCTGTCTCCCCAACTG 20 61.4 60% 
5 Exon 4-5 F TCCTCCTTCTTCCTGTGCTG 20 59.4 55% 
6 Exon 4-5 R TAGCACCTCCACTACCCCAC 20 61.4 60% 
7 Exon 6 F AGAGATGGGGACGAAGCTG 19 58.8 57.9% 
8 Exon 6 R CCCAACTATAAACTCCTGTGGC 22 60.3 50% 
9 Exon 7Af CACACAGTGGGGACCCTG 18 60.5 66.7% 
10 Exon 7aR GATGGGGATGGAGCTGAG  18 58.2 61.1% 
11 Exon 7bF TTCTCAGCTCCATCCCCATC  20 59.4 55% 
12 Exon  7bR CCCACCATAATAGAAGTCCCC  21 59.8 52.4% 
13 Exon 7cF TTGGGAGACCTGGTGGCTGC  20 63.5 65% 
14 Exon 7cR CTCCGTGGTCAGCTCCTCAG  20 63.5 65% 
 
1Oligo: Oligonecleotide; 2Tm: melting temperature, 3F: forward primer; 4R: reverse primer.  
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2.2.8.4   DNA Amplification by PCR 
 
The PCR mixture with final 1X reaction was used for DNA amplification. A final volume 
of 25µl was used and  included 1 μL genomic DNA (~100 ng), 20 μL PCR buffer (buffer: 
75 mM Tris-HCl, pH 8.8 at 25°C, 20 mM ammonium sulfate,1.5 mM MgCl2 and 0.625 
Units ThermoPrime Taq DNA Polymerase) and 1 μL of each amplification primer (10µM 
each). PCR amplification was carried out in a PCR system (DNA Engine, PTC-200, 
Peltier Thermal Cycler; Scandinavian Diagnostic Services (SDS) Company).  A no 
template control (NTC) reaction was performed as negative control. An Apae DNA was 
also sequenced for exon 7 B and C as positive control for the wild type unmutated 
GBTG1 gene. Thermal cycling was performed as shown in Table2.5. 
 
Table 2.5. Thermal cycling program for amplification of Exon 7c. 
 
PCR program 
 
Exon 7 amplification 
 
       Cycle sequencing 
. Temp Time. 
 
         Temp        Time  
Initial denaturation  95 °C 1min          …….        …….. 
 
  
 
 
Denaturation 94 °C 30 sec          96 °C       30 sec 
Annealing 57 °C 30 sec          50 °C       15 sec 
Extension 72 °C 1 min          60 °C       4 min 
Final extension  72 °C 20 min          ……..        …….. 
     
Keep in machine 6 °C ∞          6 °C           ∞ 
No. of cycles 30            25  
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2.2.8.5 Agarose gel electrophoresis 
 
For visualization, Agarose gel electrophoresis was used for separating and analysing 
DNA. A 1.5% agarose gel was prepared by mixing 0.9 gm Agarose LE (Low 
Electroendosmosis), PRONAROSE with 60 ml of 0.5TBE (54g Tris, 27,5g borate, 20ml 
0.5 EDTA) buffer. Then, the DNA was visualised in the gel by addition of 4 μL Nucleic 
Acid Gel Stain, Gelstar, Lonza  after leaving it to cool down to about 60°C. A 5 μL of the 
PCR product were electrophoresed on agarose gel. A PCR product from colourless PCR 
Master Mix was mixed with 1.5μL of Gel loading Dye (6x) and then loaded on the gel. In 
the first lane, 3 μL of 100 bp DNA OGeneRuler Gel agarose ladder was added and used 
as a guide. All amplification products were separated by high-voltage electrophoresis 
(100 voltage for 45 min). Then, the gel was placed on a UV light transilluminator to 
visualize the DNA fragments.  
 
2.2.8.6   Purification of PCR Product 
 
Purification for PCR product was done using (GeneJET PCR purification kit) from 
Thermo Scientific Company which uses a silica-based membrane technology in the form 
of a spin column. A 1:1 volume of Binding Buffer was added to complete PCR mixture 
then was mixed thoroughly. A 30 µL of the solution from step 1 was transferred to the 
GeneJET purification column (preassembled with collection tubes). It was centrifuged for 
30-60 s. Then, the flow-through was discarded. A 700 µL of a concentrated Wash Buffer 
was added (it was diluted at first with the ethanol) to the GeneJET purification column. 
Then it was centrifuged for 30-60 s. After that the flow-through was discarded and the 
purification column was placed back into the collection tube. The empty GeneJET 
purification column was then centrifuged for an additional 1 min to completely remove 
any residual wash buffer. The GeneJET purification column was transferred to a clean 
1.5 mL microcentrifuge tube. A 50 µL of Elution Buffer (10 mM Tris-HCl, pH 8.5) was 
added to the centre of the GeneJET purification column membrane and then was 
centrifuged for 1 minute. The GeneJET purification column was discarded and the 
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purified DNA was stored at -20°C [89]. The quality and quantity of purified PCR product 
was assessed by agarose gel electrophoresis. 
 
2.2.8.7 Sequencing of PCR products 
 
Sequencing was done by dye terminator cycle sequencing chemistry. A 4 μL pure PCR 
product, 8 μL ddH2o (double distilled water), 1 μL Primer, 2 μL BigDye Terminator 
v1.1/3.1 Sequencing Buffer and 6 μl BigDye Sequencing Buffer were mixed in a PCR tube. 
This mixture was subjected to 25 three-temperature cycles (See Table 2.6, Cycle 
sequencing program).The sequencing reaction is summarized in Table 2.6. 
 
Table 2.6. Cycle sequencing reaction. 
 
 
 
 
 
 
 
 
 
 
2.2.8.8 Ethanol/EDTA Precipitation 
 
To precipitate the 20 µL sequencing reactions, a 100 μL of 99% ethanol and 5 μL of 125 
mM EDTA were added to each PCR tubes. The mixture was incubated for 30 min to 4 
 
Reagent  
 
 
Concentration 
 
Volume  µL. 
 BigDye Terminator v1.1/3.1 Sequencing Buffer 5X 2 
BigDye Sequencing Buffer 5X 6 
Primer  10X 1 
Template  4 
dd water  8 
Final volume  20 
 
Mix well and spin briefly. Then, the tubes were placed in a thermal cycler  and the 
volume was set to 20 µL. 
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hours at room temperature, and centrifuged for 20 min at 12000g. The next step followed 
immediately and if this was not possible, the tubes were spined for an additional 2 min 
before performing the next step. Ethanol was discarded and the samples were washed 
with 200 μL of 70% Ethanol. Then centrifuged for 5 min at the same speed and air dried. 
After that, 20 μL HiDi formamide was used to resuspened the single-stranded sequencing 
amplicons. 
 
2.2.8.9   Sequencing 
 
Sequencing was performed using DNA sequencing machine (ABI PRISM, 310 Genetic 
analyser, Applied Bio systems, U.S) which is based on Capillary electrophoresis (CE) 
and used POP-6 performance optimized polymer 6. 
 
2.2.8.10   Analysis of DNA sequence 
 
BLAST (Basic Local Alignment Search Tool) searches /CDS feature (complete DNA 
sequence) was used to compare our DNA sequences with RefSeq, (Homo sapiens 
globoside alpha-1,3-N-acetylgalactosaminyltransferase (GBGT1), RefSeqGene on 
chromosome 9, Accession NG033868). Sequences were first examined for 2 
polymorphisms in exon7; (c.688G.A [p.Gly230Ser] and (c.887A.G [p.Gln296Arg]. As a 
positive control we sequenced DNA from an individual positive for FORS1 antigen (Apae 
variant individual) and looked for Homo sapiens globoside alpha-1,3-N-
acetylgalactosaminyltransferase (GBGT1) (Forssman expressing variant Apae #1, 
Accession HE583597). Other programs were used such as  Exome Variant Server (EVS 
gene); to look for all GBGT1 variants discovered before and the role of each variant 
(polyphenotyping) in pathogenicity was examined using the Reference SNP (Reference 
Single Nucleotide Polymorphism)  identifier and Ensemble Genomes Browser; to provide 
complete genome assembly.  
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2.2.10   Newborn Samples 
Some studies have reported the presence of the FORS antigen in certain human 
embryonic and normal gastric mucosa in fetal gastrointestinal tissues. In addition, 
previous Swedish study showed that FORS antigen is absent in adult and present in 2 out 
of 8 newborns (unpublished data), so we aimed to investigate the expression of Forssman 
antigen in newborns in Palestine. Seventy three samples were collected from healthy 
newborns from different hospitals in Hebron and Beit-Jala cities (Table 2.7), West Bank, 
in order to investigate Forssman antigen expression in newborns. The samples were from 
1-5 days old babies, except one sample that was collected from a 10-days old baby. 
Twenty five of these samples were venous blood collected by venipuncture and the other 
forty eight samples were cord blood samples that were collected immediately after 
delivery from the umbilical cord. All samples were withdrawn by experienced medical 
technicians at the respective medical centers in Hebron and Bethlehem. The RBC's that 
have been separated from cord blood were washed using the same steps used earlier for 
adults samples but for five times instead of three because to get rid of Wharton’s jelly, to 
be able to use them for blood grouping. The DNA for all samples was extracted from the 
separated buffy coat using the Genomic DNA Mini Kit (Blood/Cultured Cell) by five 
steps: sample preparation, cell lysis, DNA binding, washing and DNA elution.  An 
Amplification Refractory Mutation System (ARMS) PCR primers were used to detect the 
presence of A887G mutation at codon Gln269Arg in 30 samples. DNA sequencing was 
done for three samples to verify the ARMS PCR results.   
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Table 2.7: List of medical centers from which the study samples were collected. 
 
Medical Center Name 
 
Number of collected samples 
Beit Jala governmental hospital-Beit Jala city  8 
PRCS *specialized hospital-Hebron city 22 
Alia Governmental Hospital- Hebron city 10 
Al -Ahli hospital – Hebron city 33 
Total 73 
*PRCS: The Palestine Red Crescent Society  
 
2.2.11    Statistical analysis  
 
Descriptive statistics including mean and SD were calculated for all data. The correlation 
between presence/absence of anti-Fs antibodies and polymorphisms of GBGT1 gene was 
investigated by Spearman Coefficient correlation. IBM SPSS statistical software version 
22 was used for all statistical calculations. Significance was set at P < 0.05. 
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Chapter Three 
 
III   Results 
 
The general characteristics of all participants (Palestinian donors) obtained from the 
study questionnaire were analyzed and summarized in Table 3.1. 
 
Table 3.1.  Palestinian donors (n= 211) baseline characteristics. Results are expressed as mean 
± SD for age variable, and as percentage (%) for the other variables.  
Cc 
Gender  M: 51.7%         F: 48.3% 
Age (year)  Mean = 20.52    SD ± 2.471 
Previous history of blood transfusion  Yes = 1.4%        No = 98.6% 
Pregnant before Yes = 2.8%        No = 97.2 % 
Previous surgery or medical operation  Yes = 19.9%      No = 80.1 % 
Chronic or hereditary diseases Yes = 3.3%        No = 96.7 % 
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3.1   ABO grouping and Rh typing 
 
The results of ABO and Rh typing for Palestinian samples are summarized in Table 3.2. 
Those for Portuguese Blood samples are summarized in Table 2.3 (in chapter 2). All 
Swedish blood samples were blood group O type. Blood groups A and O were the most    
common blood groups among Palestinian subjects.  
 
Table 3.2.  Phenotypes of ABO blood groups and Rh (D) antigen for the Palestinian donors. 
Results are expressed as frequency. 
 
 
Rh(D) 
Total 
count 
Negative 
(n) 
Positive 
(n) 
Blood 
grouping 
A 8 70 78 
AB 1 21 22 
B 5 31 36 
O 5 70 75 
 
Total 
 
19 
 
192 
 
211 
 
 
3.2   FORS1 Antigen typing 
 
All the samples were negative for FORS1 antigen by serological testing using anti-Fs 
antibodies. 
 
3.3   Anti-Fs antibodies 
 
More than one method were used for anti-Fs antibodies detection. Then, sheep red blood 
cells protocol was used (see section 2.2.7.4) to test plasma of study subjects. A summary 
of the results of all anti-Fs testing methods are shown in Table 3.3.  
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Table 3.3 Summary of all anti-Fs testing methods. 
 
 
Method used for anti-Fs 
detection  
 
 Positive Control 
 
 Negative Control 
 
FORS1 
Ag 
Source 
 
Conc. 
 
Technique  
 
1:100 
HPL 
 
Anti-Fs 
culture 
 
CellStap. 
 
Apae W** 
 
Apae B** 
 
Untreated 
 O RBC 
   
   
   
 F
S
L
-F
s-
 K
od
ec
yt
es
 
 
25 
µg/mL 
 
Gel card 
 
Agglutination 
 
No 
agglutination 
 
No 
agglutination 
 
No 
agglutination 
 
Agglutination 
 
No 
agglutination 
 
 
50 
µg/mL 
 
Gel card 
 
Agglutination 
 
Agglutination 
 
No 
agglutination 
 
Agglutination 
 
Agglutination 
 
No 
agglutination 
 
Flow 
cytometry 
 
Agglutination 
 
Agglutination 
 
No 
agglutination 
 
Agglutination 
 
Agglutination 
 
No 
agglutination 
 
Sheep 
RBC 
 
0.8% 
 
Gel card 
 
Agglutination 
 
Agglutination 
 
No 
agglutination 
 
Agglutination 
 
Agglutination 
 
…………. 
 
*Unexpected results are shown by red colour.  
**Apae W and Apae B are both FORS1 positive individuals. 
FSL-Fs: Function-spacer-lipid KODE technology construct for Forssman glycolipid. 
 
For investigation of anti-Fs antibodies, first we had used 25µg/ mL penta- FORS 
Kodecytes-FSL technology and the gel card system based on hemagglutination principle 
(protocol 2.2.7.2).  In this regard, as a positive control, Helix pomatia lectin (diluted 
1:100) gave positive reaction (agglutination) with penta- FORS Kodecytes. On other 
hand, a negative result was observed when these kodecytes were reacted with anti-Fs 
antibodies (harvested from cell culture supernatant. RBC preservative solution (CellStap) 
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and Apae W plasma (one of the FORS1 positive individuals) gave a negative results as 
expected and were used as negative controls. Unexpectedly, Apae B plasma (another 
FORS1 positive individual) gave positive result. To exclude possible cross reactions that 
may be caused by other red cell antigens, all positive and negative controls were tested 
also with untreated type O red blood cells as another negative control and the result was 
negative, as shown in Figure 3.1. 
 
 
Figure 3.1. Results of 25µg/ml kodecytes FSL-FORS 5 (penta Forssman kodecytes) by using 
gel card method. Anti-Fs; anti-Forssman antibodies without precipitation, HP; 1:100 Helix 
pomatia, W; Apae W plasma, B; Apae B plasma and CellStap; cell stabilization solution. 
 
We made precipitation for anti-Fs antibodies culture to concentrate the antibodies by 
using ammonium sulfate (protocol 2.2.7.1).  Same results were obtained from   
antibodies without precipitation in heamagglutination test by gel card method, see Figure 
3.2. 
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  Figure 3.2. Results of precipitated anti-
Fs     antibodies with 25µg/ml kodecytes 
FSL-FORS by using gel card method. 
Anti-Fs +; anti-Forssman with 
precipitation, Anti-Fs - ; anti-Forssman 
without precipitation HP; 1:100 Helix 
pomatia, W; Apae W plasma, B; Apae B 
plasma and CellStap; cell stabilization 
solution 
 
Since plasma from both Apae W and B individuals should be negative for anti-Fs 
antibodies, new kodecytes were prepared with higher concentration of FSL penta sugars 
to resolve this anomaly. In the second part of 2.2.7.2 protocol, the concentration of FSL 
was increased from 0.25 to 0.50 µg/mL.  With an FSL concentration of, 50µg/ml, a 
positive reaction (agglutination) was observed with Apae W, Apae B and anti-Fs antibodies, 
as shown in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
 
IgM 
IgG 
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Figure 3.3. Comparison between the result of 25µg/ml and 50µg/ml kodecytes FSL-FORS 5 
(penta Forssman kodecytes) gel card method. Anti-Fs; anti-Forssman without precipitation, 
HP; 1:100 Helix pomatia lectin, W; Apae W plasma, B; Apae B plasma and CellStap; cell 
stabilization solution. 
 
These results were confirmed by flow cytometry analysis (2.2.7.2 protocol, flow 
cytometry part), see Figure 3.4. 
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Figure 3.4.  Results of anti-Fs testing using 50µg/ml kodecytes FSL-FORS and flow 
cytometry method. A) Negative control (cellStap), B) Random sample IgM, C) Positive control 
(anti-Fs culture IgG), D) Positive control (anti-Fs culture IgM), E) Negative control (Apae B IgG) 
and F) Negative control (Apae B IgM). The percentage in each figure represents the percent of 
gated population of interest (anti-Fs antibodies population).  
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To resolve this discrepancy in typing for anti-Fs antibodies, we tested diluted plasma 
against kodecytes prepared with 50µg/ml FSL-Fs penta-saccharides to test the effect of 
dilution of agglutination for kodecytes.(see section 2.2.7.3) Overall, the results observed 
with diluted plasma didn’t give a large difference from those with undiluted plasma. One 
note was, with 1:8 dilution of plasma, the results of the gel card correlated well with the 
results of flow cytometry analysis using undiluted plasma (Figure 3.4). An Apae B IgG 
and IgM tests gave 2 populations of RBCs (mixed field reaction) in both methods while 
with gel card and undiluted Apae B plasma they gave positive result with one population. 
We observed also most of diluted plasma gave negative results with IgG after dilution. 
Table 3.4 summarizes these results. 
 
Table 3.4 Reaction pattern for detection of anti-Fs antibodies in diluted plasma from 
FORS1 antigen positive individuals (Apae W and Apae B) and FORS1 negative individual 
(PAM10). 
 
Dilution 
titer 
Apae W Apae B PAM10 
IgG IgM IgG IgM IgG IgM 
1:2 w+ + + + + + 
1:4 - + + + + + 
1:8 - w+ MF MF w+ + 
1:16 - - + + - w + 
1:32 - - + + - w + 
1:64 - - - + - - 
1:128 - - - + - - 
1:256 - - - - - - 
 
*w +: weak positive reaction (agglutination), +; positive reaction (agglutination), _; negative 
reaction (no agglutination), MF; mixed field and PAM: one of the Palestinian samples. 
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Using sheep RBCs as platform for testing for anti-Fs (2.2.7.4 protocol) and gel cards are 
summarized in Table 3.5. The anti-Fs and plasma from the individual Apae B agglutinated 
with the sheep RBCs, while the plasma from the individual ApaeW didn't agglutinate in 
the NaCl Card (IgM) but reacted weakly in the AHG (IgG) card. In some cases, the 
reactions were stronger when unwashed RBCs were used. 
 
The reaction pattern for plasma from ApaeB and ApaeW individuals and Anti-Fs with 
sheep RBC suspended in saline were as follows:  plasma of ApaeB and Anti-Fs gave 
positive reaction while with  plasma of Apae W individual gave  negative reaction and 
thus remained consistent with previous test ( 2.2.7.2). 
 
The reaction patterns for diluted plasma with sheep RBCs were; negative reaction with 
Apae W plasma, positive reaction was observed with Apae B plasma (titer 1:2) and positive 
reaction with IgM anti-Fs (titre 1:4).  
 
Table 3.5. Reaction patterns of sheep RBCs reaction with Apae W plasma, Apae B plasma and 
anti-Fs antibodies.   
 
Suspension 
solution 
Apae W Apae B Anti-Fs 
Washed 
sheep RBC 
Unwashed 
sheep RBC 
Washed  
sheep RBC 
Unwashed 
sheep RBC 
Washed 
sheep RBC 
Unwashed 
sheep RBC 
IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM 
LISS W+ - W+ - + + + + + + + + 
Bromelain 
Enzyme 
W+ - W+ - + + + + + + + + 
Saline - + + 
Serial 
dilution 
- at all dilutions +  at 1:2 dilution 
-  at 1:4 and higher dilutions 
+ at 1:4 dilution 
- at 1:8 and higher dilutions 
+: positive reaction (agglutination), - : negative reaction (no agglutination), W+: weak positive 
reaction, Br enzyme is bromelain and LISS: Low Ionic Strength Saline. 
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3.3.1 Results of anti-Fs antibodies in Palestinian samples (using sheep RBCs) 
 
The results showed that 6.2% of samples were negative for IgG anti-Fs, 4.3% of samples 
were negative for IgM anti-Fs and 3.8% (8/211) of samples were negative for 
both IgM and IgG anti-Fs. The absence of anti-Fs (both IgG and IgM) was more common 
among males compared to females, where seven of the eight samples which were 
negative for both IgG and IgM anti-Fs were males. However, stronger reactions 
(agglutinations) were observed also in females (Table 3.6). 
 
Table 3.6 Frequency of IgG and IgM anti-Fs antibodies in Palestinian subjects according to 
gender. 
 
 
Gender 
 
IgG anti-Fs antibodies 
     
IgM anti-Fs antibodies 
 
    IgG and IgM 
Neg. 
 
V +1 +2 +3 +4           Neg. V +1 +2 +3 +4            Neg. 
Female  
 
3 1 13 26 31 25   1 7 19 21 28 24              1 
Male 
 
10 6 18 29 27 16   8 5 27 23 29 14               7 
Total 13 7 31 55 58 41  9 12 46 44 57 38                8 
 
* Neg.: negative and V: visible.  
  
 
 
The majority of samples showed consistent results when tested for both IgG and IgM 
anti-Fs antibodies. Additionally, the majority of samples gave similar reaction strength 
when tested for both IgG and IgM anti-Fs (Table 3.7). However, seven samples which 
tested negative for anti-Fs antibody in the tube method, showed positive reactions in gel 
cards (+2, +1, weak reaction or double populations).  
52 
 
Table 3.7.Comparison between the reaction patterns in IgG & IgM anti-Fs antibodies. 
Results are expressed as frequency. 
 
 
R
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ct
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n
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Reaction strength for IgG 
+1 +2 +3 +4       V Neg. 
 
+1 21 17    4    0       1 3 
+2 6 16    19     2      0 1 
+3 1 17    24     14       1 0 
+4 2 4    6     22        2 1 
V 0 1    5     3        3 0 
Neg. 1 0    0    0        0 8 
                                            *Neg.: negative and V: visible. 
 
There was no correlation between presence/absence of anti-Fs IgM and IgG antibodies 
and GBGT1 polymorphisms (p= 0.408) and (p=0.433), respectively.  
 
The frequency of samples negative for anti-Fs antibody showed variations in Ig’s classes, 
among blood groups (Table 3.8). The highest percent of samples negative for anti-Fs was 
in AB blood group, it was 13.6% in AB individuals and 1.4% in all individuals. 
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Table 3.8. Correlation between anti-Fs antibody negativity and blood groups.  
 
 
Blood 
group 
 
N 
 
No. of individuals 
negative for both 
IgG and IgM (n) 
 
% of individuals negative for 
both IgG and IgM in specific 
group 
 
% of individuals 
negative for both IgG 
and IgM in all 
samples 
A 78 1 1.3 % 0.47 % 
B 36 2 5.6 % 0.95 % 
AB 22 3 13.6 % 1.4 % 
O 75 2 2.7 % 0.95 % 
Total 211 8 -- 3.8 % 
 
 
 
Stronger agglutination reactions (grades +3 or +4) for IgG anti-Fs were observed in A 
and O blood groups, 53.8% and 53.3%, respectively. With IgM anti-Fs antibody stronger 
reactions were also observed in A and O blood groups, 51.3% and 48% of samples, 
respectively. The frequency of samples that showed strongest reaction in the IgG reaction 
(4+) is higher among group A compared to group O. This also applies for IgM reaction. 
In contrast, weaker agglutination reactions (+1 or visible) for IgG and IgM anti-Fs were 
observed in B blood group, 25% and 36.1% for IgG and IgM, respectively. Furthermore, 
in AB blood group, it was 18.1% and 36.3% for IgG and IgM, respectively (Table 3.9). 
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Table 3.9. Reaction strength for IgG  & IgM anti-Fs antibodies  in relation to blood group. 
  
 
Reaction in IgM test tube 
 
Total 
  
 
+1 
 
+2 
 
+3 
 
+4 
 
V 
 
Neg. 
 
Blood 
group 
A 13 19 22 18 5 1 78 
AB 7 2 5 3 1 4 22 
B 11 6 9 6 2 2 36 
O 16 17 23 13 4 2 75 
 
Total  47 44 59 40 12 9  
 
   
Reaction in IgG test tube 
 
Total 
   
+1 
 
+2 
 
+3 
 
+4 
 
V 
 
Neg. 
 
Blood 
group 
A 11 19 20 22 3 3 78 
AB 4 5 6 3 0 4 22 
B 9 11 9 4 0 3 36 
O 12 16 26 14 4 3 75 
 
Total  36 51 61 43 7 13  
 
*Neg.: negative and V: visible 
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The results of anti-Fs antibodies testing according to receive a blood transfusion 
history are shown in Table 3.10. 
 
 
Table 3.10: The FORS antibody results according to receive a blood transfusion. 
Results are expressed by a frequency.  
 
 received blood transfusion Total 
No Yes 
FORS antibody 
test 
                Negative 8 0 8 
                 Positive 200 3 203 
Total 208 3 211 
 
 
3.4    GBGT1 sequencing results 
 
After serological characterization of the blood samples, the next step aimed at testing 
samples for the Gln296Arg and Gly230Ser mutations that are responsible for the FORS1 
antigen negativity in human.  For this purpose, six primer pairs were designed to 
sequencing exons 2 to 7 of the GBTG1 gene. Exons 3 to 7 of the GBTG1 gene were 
sequenced for eight samples (6 from Palestine and 2 from Sweden). Seventy samples 
were sequenced for whole exon 7 (using primer pairs B and C). The remaining samples 
were sequenced only for exon 7 and specifically the sequencing targeted the 3’end of 
exon 7 covering the sequence flanking the two main mutation, Gln296Arg and 
Gly230Ser (using primer pair C) (Figure 3.5). The respective exons were amplified using 
PCR and then PCR products were purified from agarose gel (Figure 3.6) and used for 
DNA sequencing.  
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10                               20                              30                          40                          50 
MHRRRLALGL     GFCLLAGTSL        SVLWVYLENW    LPVSYVPYYL      PCPEIFNMKL  
        60                            70                           80                            90                         100 
HYKREKPLQP       VVWSQYPQPK     LLEHRPTQLL      TLTPWLAPIV       SEGTFNPELL  
       110                          120                         130                         140                       150 
QHIYQPLNLT        IGVTVFAVGK      YTHFIQSFLE        SAEEFFMRGY      RVHYYIFTDN  
       160                              170                      180                     190                       200 
PAAVPGVPLG      PHRLLSSIPI       QGHSHWEETS       MRRMETISQH     IAKRAHREVD  
       210                            220                        230                           240                    250 
YLFCLDVDMV     FRNPWGPETL      GDLVAAIHPS        YYAVPRQQFP     YERRRVSTAF  
       260                              270                      280                           290                    300 
VADSEGDFYY     GGAVFGGQVA     RVYEFTRGCH       MAILADKANG    IMAAWREESH  
       310                             320                           330                    340  
LNRHFISNKP        SKVLSPEYLW       DDRKPQPPSL       KLIRFSTLDK       DISCLRS 
Figure 3.5   Amino acids for GBGT1 protein that covered by exon 7C sequenced in this 
study (by red color). The picture modified from the reference: UniProtKB – ID: 
Q8N5D6 (GBGT1_HUMAN). 
 
 
 
Figure 3.6 Agarose gel electrophoresis for PCR products of GBTG1 gene exon 7 following 
purification of PCR amplicons from agarose gel.  
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3.4.1 DNA sequence variants 
 
Exon 7 was sequenced in all study samples and Apae #2 individual was used as a positive 
control for active GBGT1 (R296Q polymorphism). DNA sequencing revealed that all 
samples have Gln296Arg and Gly230Ser polymorphisms. 
 
Regarding Palestinian samples, an additional four polymorphisms were reported, one of 
them was a novel polymorphism (c.727 C→T p. R243C). Two SNPs were silent 
mutations (c.696 C→T p.Y232=, c.870 C→T p. G290=) and two SNPs were missense 
mutations (c.727 C→T p. R243C, c.728G→A p. R243H) (Table 3.11). To check for 
validity of DNA sequence, samples showing one of the aforementioned polymorphisms 
were sequenced using forward and reverse primers and/or the sequence was repeated 
twice. The novel SNP (c.727 C→T p. R243C) was found in Palestinian female, 19 years 
old.  
 
 
 
Table 3.11   Summary of frequency and percent of each SNP in Palestinian subjects.  
SNP Frequency (n=211) Allele frequency 
(n=422 
chromosomes) 
(%) 
N Heterozygote Homozygote 
c.727 C→T p. R243C 1 1 0 0.2 
c.728G→A p. R243H 4 4 0 1.0 
c.696 C→T p.Y232= 2 2 0 0.5 
c.870 C→T p. G290= 14 13 1 3.6 
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Regarding the Swedish samples, all 47 samples were homozygous for the two common 
mutations (Gln296Arg & Gly230Ser). Two samples were hetrozygous for the 
polymorphism (c.870 C→T, p. G290=).  
 
Only eighteen Portuguese random donors were tested for exon 7C sequencing.  All 
samples were homozygous for the two common mutations (Gln296Arg & Gly230Ser) 
(Figure 3.7). Only one sample was heterozygous for the polymorphism (c.870 C→T, p. 
G290=). Table 3.12 summarizes all SNPs/variants observed in the study samples.  
 
 
 
Figure 3.7   The two common mutations (Gln296Arg & Gly230Ser) GBGT1 exon 7 in 
human.  
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Table 3.12   DNA variants that were observed in the study samples. 
 
*Variant Pos.: is the SNV (Single Nucleotide Variant) location on the chromosome, rs ID 
(rsids):  is an accession number used by researchers and databases to refer to specific SNP and it 
stands for (Reference SNP cluster ID), sometimes called dbSNP (Single  Nucleotide 
Polymorphism Database) reference SNP identifier, Alleles: it refers to a change from a reference 
allele to an alternate allele, All Allele #: is the observed allele counts in all populations (European 
American population (EA) and in African American population (AA). PolyPhen: is the 
prediction of possible impact of an amino acid substitution on protein structure and function 
based on Polymorphism Phenotyping (PolyPhen2) program. All the data in this table were 
extracted from Exome Variant Server program. 
 
The four SNPs listed in Table 3.12, were found in the heterozygote state, except one 
sample (Palestinian sample) was found to be homozygous for the “p.G290=” SNP, 
(Figure 3.8). The prevalence of SNPs relevant for this study are shown in Table 3.13  
 
Variant 
position*Chr
:bp 
 
rs ID* 
 
Alleles
* 
 
cDNA  
change 
 
Protein 
change 
 
PolyPhen* 
 
 
All Allele # * 
9: 136029280 rs143563851 A+G c.728G→A p.(R243H) probably-
damaging 
T=10/C=1299
6 
9: 136029279 rs759428295 C+T c.727C→T p.(R243C) probably-
damaging 
Novel  
9:136029312 rs34691037 C+T c.696C→T p.(Y232=) Unknown A=374/G=126
32 
9:136029138 rs35902535 
 
C+T c.870C→T p.(G290=) Unknown A=818/G=121
88 
60 
 
 
Figure 3.8   Representative sequence chromatograms. A) Positive control Gln296Arg (Apae 
DNA), B) Novel mutation R243C, C) heterozygous SNP G290= and D) Homozygous SNP 
G290=.  
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Table 3.13   Prevalence of SNPs relevant for this study. Values are given as the percentage of 
tested alleles in random donors.    
 
 
SNP ID 
  
c.870 C→T p. 
G290= 
 
c.696 C→T 
p.Y232= 
 
c.728G→A 
p. R243H 
 
c.727 C→T 
p.R243C 
 
Study populations (%) 
Palestinian samples (n=211) 
Swedish samples (n=47) 
Portuguese samples( n=18) 
 
 
6.6%*** 
4.3% 
5.6% 
 
 
0.95% 
0 
0 
 
 
2% 
0 
0 
 
 
0.5% (Novel) 
0 
0 
ENSEMBL Genetic 
Variation*/MAF 
0.042 0.027 0.001 Not listed 
EVS**/MAF 6.2894 2.7856 0.0769 Not listed 
 
*ENSEMBL Genetic Variation available at: 
http://asia.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG000001482
88;r=9:133152948-133163945. Accessed on April 24th, 2016. 
 
**EVS: Exome Variant Server: available at: 
http://evs.gs.washington.edu/EVS/ServletManager?variantType=snp&popID=AfricanAmerican&
popID=EuropeanAmerican&SNPSummary.x=35&SNPSummary.y=10. Accessed on May 2nd, 
2016. 
MAF: minor allele frequency. 
*** One of screening-positive samples was homozygous for c.870 C→T. 
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3.4.2 Result for newborn sample testing  
 
Fifty newborn samples were collected from Palestinian hospitals and tested them for 
FORS1 antigen. Furthermore, 30 samples were tested for the Gln296Arg mutation using 
ARMS PCR. Serological grouping of newborn RBCs for Forssman antigen (FORS 1) 
revealed that all newborns were negative for this antigen. The serological results of 
newborn samples support serological grouping of our adult samples. ARMS PCR showed 
that the 30 samples tested all having the Gln296Arg mutation, which have been reported 
previously to cause inactivation of the Fs synthetase. To confirm the ARMS PCR results, 
exon 7 of GBGT1 gene was amplified and sequenced completely for three samples. DNA 
sequencing revealed the presence of the two common mutations (Gln296Arg & 
Gly230Ser) and the C allele at the SNP (c.363 C>A described earlier by Svensson et al. 
2010) was normal in all 3 samples analysed by sequencing. 
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Chapter Four 
 
IIII    Discussion  
 
Forssman antigen, one of the most well-known heteroantigens, was recently reported to 
be present in normal human hematopoietic tissue. Present on glycolipids, it is a normal 
constituent of fetal and various normal tissues and it was elevated in various cancer 
tissues [90, 91]. The study of FORS blood group has many beneficial aspects. First, the 
ability whether it express the Forssman glycolipid has implications for the host tropism of 
several infectious diseases. Second, natural anti-Fs antibodies, present in high 
concentration in many humans could be of immunological barrier to transfusion/ 
transplantation therapy. The sera of cancer patients displayed a decreased anti-Fs 
reactivity as compared with sera of a control group [53], so they also can be used as anti-
tumor marker and to determine the recurrence in patients with cancer postsurgically. In 
addition, GBGT1 gene encoding the Forssman synthetase is evolutionarily related to the 
ABO gene. Sequencing of that gene to detect the mutation (Gln296Arg) is the preferable 
test for FORS1 human positivity. Moreover, different mutations in GBGT1 gene could be 
found in different populations and some relation between the Fs gene mutations and 
different diseases. 
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4.1   Blood grouping 
 
Monoclonal anti-Fs IgM from rat cell culture supernatant was used to test FORS1 
grouping of the samples. It was one step, simple, fast and appropriate method for all 
blood group types.  In contrast, the classical test for FORS1 antigen using the Helix 
pomatia (HP) lectin has many advantages but it needs two steps. By using HP lectin for 
FORS grouping, only for non-A blood groups could be tested. Helix pomatia lectin has 
been used to recognizes N-acetylgalactosaminylated residues and it has been used in 
cancer research as an indication of metastasis behavior  and poor patient prognosis [92] 
because of its specificity for cancer cells in the very early stages of the metastatic 
process. The binding preference was established to be Forssman antigen (strongest 
preference first), blood group A substance and Tn antigen [76]. Moreover, when various 
human cancer cell lines were transplanted into severe combined immune deficient mice, 
only the HPA positive cell lines metastasized. So the GalNAc-containing cancer epitopes 
on the surface of cancer cells could be serve as cancer- vector agent in tranplantation 
process [93]. Both the Tn antigen present on mucins and the Forssman antigen present on 
glycolipids are good candidates .In 1993, Oriol et al. used HP lectin to stain porcine 
tissues for the Forssman antigen [94].  
 
In this study, we have tested 211 Palestinians, 47 Swedish and 18 Portuguese individuals 
for FORS1 antigen. All samples tested in this study were negative for the FORS1 antigen. 
These findings are consistent with previous reports that revealed that the prevalence of 
FORS1 antigen positivity is <0.1% [51]. On other hand, previous reports stated that 75% 
of healthy men and women have anti-Fs antibodies. This would suggest also that the 
majority of humans are Forssman antigen-negative [95], although the lack of antibodies 
cannot be used to deduce  the phenotype of FORS1 antigen.  
 
Different ABO and Rh blood groups were observed by reacting red blood cell suspension 
of the samples with monoclonal antibodies for these antigens. Forward or cell grouping 
for FORS1 antigen results showed that there is no relationship between ABO, Rh blood 
group system and FORS blood group system since all study subjects were negative for 
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FORS1 antigen regardless of the ABO and Rh phenotype. Reverse or serum grouping for 
anti-Fs antibody cannot be performed on plasma samples due to the absence of FORS 
positive human cells, therefore, alternative cells were used for this purpose as discussed 
below. 
 
4.2   Anti-Fs antibodies testing 
 
According to the study by Levine  (1978), the incidence of anti-Fs in the normal 
population is 75%. Levine has analysed anti-Fs by age groups, a lower incidence of anti-
Fs was found in the adult population [95]. These results can perhaps be attributed to the 
accumulated effect of immune responses to infections and infestations with increasing 
age [95]. As we mentioned before, FORS1 antigen is also expressed in some normal 
tissues such as gastrointestinal epithelial, lung and kidney tissues [90]. Thus, it was 
suspected that some samples will be negative for anti-Fs antibodies, as many previous 
studies confirmed [95]. This was formulated by Burnet (1969), as the body fails to 
produce antibodies to its own normal tissues [96]. 
 
Furthermore, the absence of Forssman antibodies in some individuals can be attributed to 
two factors. First, some persons could not synthesize anti-Fs, as their immune response 
against Forssman antigen could be under genetic control. Second, Forssman antibodies 
might be produced in all persons but would be absorbed onto some normal tissues 
containing the Forssman antigen. Alternatively, Fs antigen may be shed from the tissue 
resulting in the formation of anti-Fs-Fs immune complexes. [53].  In addition, some of 
them could have very low anti-Fs antibodies titer, and they cannot be detected by the 
method used in this study, as it was not sensitive enough to detect this antibody. 
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4.2.1   FSL-FS Kodecytes  
 
In the absence of natural FORS1-positive RBCs, kodecytes were created using a 
synthetic pentasaccharide, Forssman glycolipid function-spacer-lipid (FSL-FS-5) 
constructs. These FSLs were used to upload synthetic FORS antigen onto normal group 
O RBCs (so-called kodecytes). These synthetic FORS RBCs were evaluated by 
heamagglutination test by two methods, gel card and flow cytometry methods, to asses if 
they have similarity to naturally FORS positive RBC or not. 
 
We aimed to examine if kodecytes can be used as an effective tool to study the FORS 
antibodies and then to incorporate it in all serologic practical laboratory sessions. In the 
study by Hult (2013), the kodecytes were created and designed for ABO subgroups to 
replace the flow cytometry and manual tube serology [37, 97]. Group O RBCs were 
modified with synthetic blood group A or B- FSL constructs [98] and they were used as 
weakly positive controls for ABO reagents in some countries [97]. 
 
A Penta Kodecyte gel card method based on the hemagglutination (HA) for FORS 
antibodies detection had the disadvantages of relatively poor specificity and do not offer 
fine discrimination between positive and negative FORS1 individuals. So, by using FSL-
FORS1 constructs we were not able to replace the natural FORS RBC by synthetic one. 
The Forssman kodecytes are artificial cells, so they are modified and cannot be compared 
with ordinary red cells.  Thus, we have prepared kodecytes as described previously by 
Svensson et al. (2012), with one difference; she tested anti-Fs positive plasma against 
FORS positive (Apae W and B) red cells. As a result, this discrepancy is almost certainly 
due to the difference in the way antigens are presented on the natural RBC membrane 
versus solid-phase assays and indirectly validates the importance of using natural RBCs 
in antibodies testing in routine laboratory [99].  
 
Furthermore, FSL-FORS1 is a synthetic analogue of natural FORS1 but both do not have 
the same structure.  The natural FORS1 glycolipid is a pentasaccharide linked to a 
ceramide lipid tail while the FSL-FORS[43]1 has identical antigen (pentasaccharide) 
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structure but with dioleoylphosphatidylethanolamine (DOPE) as the lipid tail. Another 
difference between them is the presence of approx. 2-nm spacer (equivalent in spacing to 
about two monosaccharides) in the FSL-FORS1 but not in natural FORS 1 [43] . The 
spacer in FSL is selected to provide a construct that is dispersible in water, yet will be 
spontaneously and stably incorporated into the RBC membrane [100]. Thus, the longer 
spacer can increase the affinity of the antigen when attached to RBC membranes [43].  
 
Based on our previous observations, we cannot depend on FSL-Fs kodecytes construct to 
detect specifically anti-Fs antibodies. In the future, it is possible that kodecytes treated 
with the right amounts of FSL-Fs constructs or modified to be closer in structure to 
natural FORS1-positive RBCs which are difficult to access for many laboratories (Figure 
4.1). 
 
 
Figure 4.1. Schematic diagram of the natural Forssman (FORS1) glycolipid (with a 
ceramide lipid tail)  and its synthetic analogue FSL-FORS1 (with DOPE lipid tail) [43] .  
 
 Flow cytometry (FC) methodology was also used as a highly sensitive method developed 
to detect human antibodies. It was used by Vyas (1998) for antibodies semi quantitative 
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discrimination of the amount of IgG and IgM antibodies in plasma by using a fluorescent 
labelled antibodies [101]. Flow cytometry overcome some of the shortcomings of gel 
card method such as reproducibility and quantification, whereas hemagglutination titers 
are discreet values [102]. It is well known to be a good tool to investigate the double cell 
populations or to identify weakly expressed antigens [8, 37]. 
 
For the flow cytometry (FC) method, we used fixed RBCs in the Fs antibodies testing 
because most Fs antibodies are IgM which have high ability to agglutinate RBCs, mostly 
as a pentamer but also as a hexamer. 
 
The use of diluted cells in FC method instead of using fixation solution was 
recommended by Krishnan et al. (2008), to overcome the tendency of sensitized RBCs to 
be agglutinated. It was simplified for the FC assay and it has an advantage because the 
lower cell concentration in the assay increases sensitivity [102]. As we mentioned before, 
Fs antibodies mainly belong to IgM class, so most diluted plasma containing IgG, gave 
negative results in the gel card method after the dilution step. Furthermore, if FORS1 
antigen is actually a human tumor-associated antigen, the outlook for specific 
immunotherapy may not be promising for cancer patients due to the IgM nature of human 
anti-Fs, as it consider the common problem of carbohydrate-based vaccines [53]. Still the 
FC method gave more sensitive results. It gave more clear differences between the two 
cell populations in the same sample without plasma dilution, the dilution step was 
necessary in hemagglutination by gel card to give the cell population differentiation.  
 
The level of FSL antigen required to give a positive result depends on the quality and 
level of antibody being detected. However, based on a similar study of carbohydrate 
antigens, a FSL solution of 100 μg/mL will typically result in a strong positive reaction 
[100]. For A blood type, a 100 μg/mL FSL was used and a 300 μg/mL FSL for B type 
RBC [97]. Here, the concentration of FSL used to create kodecytes was selected to give 
strong positive reactions. We increased the concentration of FSL from 0.25 to 
0.50µg/mL, according to Hult study that advised the labs to use appropriate 
concentrations of FSL construct and Hult suspected that this is the crucial point in the 
69 
 
testing procedure using the Kodecytes [98]. We found that 50 μg/mL FSL for penta-
FORS give more accurate result than the concentration 25 μg/mL. 
 
The synthetic pentasaccharide Forssman function-spacer-lipid (FSL) constructs, FORS1-
kodecytes were agglutinated with anti-Fs monoclonal antibodies and Helix pomatia lectin 
dilutes 1:100. Thereafter, both were used as positive controls for anti-Fs antibodies 
testing. In contrast, both anti-Fs and H. pomatia lectin did not agglutinate untreated 
RBCs. Kodecytes did not agglutinate when suspended in PBS and thus used as a negative 
control. The strange was the positive reaction (agglutination) of these kodecytes with 
both FORS1 positive individuals.  
 
Flow cytometry (FC) methodology was also used as a highly sensitive method developed 
to detect human antibodies. FC method was used by Vyas (1998) for semi-quantitative 
analysis of the amount of IgG and IgM antibodies in plasma using fluorescent labelled 
antibodies [101]. FC method overcomes some of the shortcomings of gel card method 
such as reproducibility, which be relevant with Nithya S. Krishnan study [102]. 
Additionally, the FC method is well known as a good method to investigate double cell 
populations such as most of Lutheran antibodies (bit like an A3 type reaction) or 
identifying weakly expressed antigens [8, 37]. 
 
The results of Apae W and Apae B plasma and kodecytes by gel card and flow cytometry 
methods led to the hypothesis that the positivity showed is caused by an antibody other 
than the anti-Fs, that is probably common in humans but at different concentrations. In 
fact, the exact biochemical reason for this is not known yet.  Possible explanations for 
such irregular results is that agglutination of kodecytes was caused by some plasma 
components such as other immunoglobulin classes like IgA, many platelets, too much 
plasma proteins or fibrin. Additionally, agglutination of kodecytes with Apae W and Apae 
B plasma may be attributed to unspecific antibodies cross-reacting with FSL synthetic 
pentasaccharide structure.   
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As we mentioned before, FORS1 antigen is a heterophile antigen, an antigen shared by 
unrelated species [58]. Also Fs antibodies are hetrophilic in nature reacting with 
substances found in unrelated species [103]. However, the presence of autoantibodies 
cross reacting with FORS antigen is not applicable here, because a previous report by 
Svensson (2012) showed that these plasma gave negative result when tested using direct 
antiglobulin test (DAT) (Svensson et al, 2012; 104). Another expectation, presence of Fs 
antigen might stimulated or induced presence of unknown specific antibody of foreign 
origin. 
 
Since 1956, Tanaka and Leduc have found that sheep RBCs gave brighter and more 
distinct reaction than other cells when tested with fluorescein-labeled antibody. For this 
reason, the sheep RBCs became the best choice for testing for anti-Fs antibodies in the 
later times [27]. In addition, Young (1979) suggested that the anti- sheep hemolysin 
present in the majority of human sera could be an alloantibody specific for Forssman 
alloantigen [53]. 
 
4.2.2   Sheep RBCs 
 
Since natural human FORS1 antigen positive RBCs are not available, we used sheep 
RBCs as a natural source of Forssman antigen for forward testing for the anti-Fs 
antibodies in the plasma of study subjects. Several reports indicated that the majority of 
healthy humans have antibodies in their sera that can agglutinate sheep RBCs. They used 
sheep RBCs but against serum levels of sheep RBCs hemolysin (xenoantibodies) or 
Forssman-like antibodies [57] not against Forssman antibodies specifically. Strokan 
(1998), tested pooled human AB sera against sheep RBCs except for binding to forssman 
and Galalpha1-3. They eliminated The Forssman and Galal- reactivity in human sera by 
immunoadsorbtion using Forssman and Galal -3Gal-immunoadsorbent columns, 
respectively [104]. Campbell (2014), confirmed that anti-Fs and anti–α-Gal antibodies 
may act through similar mechanisms [74]. The Forssman antigen is similar to the Gal 
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antigen and it has been suggested to be a possible porcine non-Gal target for human 
natural antibodies [105].  
 
Furthermore, the FORS Ag-Ab reaction may be enhanced using specific conditions like 
optimum pH and temperature [60]. However, the fine specificity and cross-reactivity of 
monoclonal antibodies are often unknown, particularly against synthetic antigens [99]. 
 
We used the sheep RBCs, although the level of Forssman antigen on the sheep RBCs is 
very strong compared to the natural FORS1 [43]. In contrary, the density of FORS 
antigen on canine RBCs and the 30 to 40μmol/L FORS1-kodecytes are equivalent to 
those of FORS1 humans. The human synthase cDNA has >80% amino acid sequence 
identity to the canine orthologue [43, 55]. The 3-5% suspension of sheep RBCs  is 
probably a heavy cell suspension and thus contributed to the false negative result with 
anti-Fs antibodies and HP lectin due to post-zone phenomenon [106]. So we used 0.8% 
sheep RBC suspension. On the other hand, a previous study by Barr, (2014) showed that 
animal RBCs cannot be reliably used to validate the presence of anti-FORS in a human 
serum, as Anti-Galili, the most abundant natural antibody in humans [107]  and other 
anti-xenoantigens are also present. In general, natural anti-a-galactosyl antibodies, 
present in high concentration in all humans [38]. Table 4.1 shows the main carbohydrate 
antigens which may have human naturally occurring antibodies.  
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Table 4.1  Known carbohydrate antigens against which humans may have naturally 
occurring antibodies [55]. 
1. Blood type A: GalNAc 1,3(Fuc 1,2)Gal 1,4GlcNAc -R 
2. Blood type B: Gal 1,3(Fuc 1,2)Gal 1,4GlcNAc -R 
3. Hanganutziu-Deicher: e.g. NeuGc 2,3Gal 1,4Glc 1-R 
4. Thomsen-Friedenreich (T or TF): Gal 1,3GalNAc 1-R 
5. Tn (TF precursor): GalNAc -R 
6. Sialosyl-Tn: NeuAc 2,6GalNAc 1-R 
7. Forssman: e.g. GalNAc 1,3GalNAc 1,3Gal 1,4Gal 1,4Glc 1-R 
8. Rhamnose-containing oligosaccharides 
9. S ulphatide I: SO4-3Gal-R 
10. P antigens 
11. I or i antigens 
 
 
 
Testing sheep RBCs by gel card method protocol gave good results with diluted plasma. 
We used 2% of LISS and bromelain enzyme treated sheep RBCs instead of 2% of papain 
treated sheep RBBCs in Sellt (1966) study [61] to improve their agglutinability by anti-
Forssman sera with both IgG and IgM antibody.  
 
Based on our results, it would be expected that the sheep RBCs have the FORS1 Ag. The 
Apae B individual plasma was agglutinated with the sheep RBCs, and didn’t look like a 
non-specific reaction because the pattern is similar to the monoclonal anti-Fs antibodies. 
Sheep RBCs can be used to test for the anti-Fs in humans because the Apae W individual 
(without anti-Fs) was negative in all testing procedures. If humans had some antibody 
nonspecific against the Sheep RBC all the testing will be positive. 
 
We therefore used a simple and rapid method for detection of Fs antibody, which is the 
gel card method. Furthermore, the gel card test is more sensitive, some samples that were 
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negative in the tube method, showed positive reactions in gel cards. So, we confirmed the 
negative result in tube method by using a gel cards. In addition, the FSL-kodecytes could 
be used to confirm the negative results found in the tube test and/or the gel cards. 
 
We have some explanations for unexpected results with Apae W and Apae B plasma. In 
general, the natural antibody is clearly linked either to carbohydrates which the host can 
produce naturally but which are normally hidden, or to carbohydrates that are 
environmentally common to it. We were interested in absence and presence of natural 
anti-carbohydrate antibodies because they have higher affinity to their host [108]. 
 
Furthermore, Nowinski (1980), observed that influenza virus and influenza vaccine both 
contain a number of glycolipids, including the highly immunogenic Forssman antigen 
and blood group A substances, so the specificity of monoclonal anti-Influenza antibody 
parallels that observed with antibodies to Forssman glycolipid found naturally in human 
sera [109]. The availability of the anti-influenza human monoclonal antibody against 
FORS antigen permits a more detailed examination of this possibility when testing for the 
human Fs antibodies, because the influenza vaccine became very common in many 
countries in last few years. 
 
In 1998, Strokan et al. noted that human anti-sheep Abs, which are bound to Forssman 
epitopes, did not bind pig kidney glycolipids which completely lacked Gal and Forssman 
glycolipid antigens [104]. 
 
In addition, we also should think about the relationship between T and Tn antigens and 
the presence and absence of the corresponding antibodies. Tn (T, Tn and Sialyl-Tn) 
antigen like Forssman antigen, both have terminal GalNAc residues, behave as A-like 
structures and described as tumor markers [110, 111]. In Lescar (2007), study, the HP 
lectin was complexed with two GalNAc containing epitopes, the Tn (alphaGalNAc-Ser) 
and Forssman (alphaGalNAc1-3GalNAc) antigens [76]. In the HPA-Forssman (Helix 
pomatia agglutinin) complex, the nonreducing GalNAc establishes the same hydrogen 
bond network as in the HPA/Tn complex.  
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In addition to Forssman antigen, several other carbohydrate antigens have been identified 
that could act as targets for human natural antibodies, and these include Gal alpha 1-
3Le(x), Hanganutziu-Deicher, Tn, and Forssman antigens [105]. Anti-HD (Hanganutziu-
Deicher) and Paul-Bunnell antibodies are also hetrophilic, as Forssman antibodies [112]. 
The prevalence of anti-HD Abs in healthy humans was originally thought to be <4%, so 
it has low incidence. The Forssman antigen has been suggested to be a possible porcine 
non-Gal target for human natural Abs  [55]. 
 
Our data showed that the frequency of anti-Fs was higher in female subjects compared to 
males. The later results showed good correlation with Hirayama  et al. (1989) study [57]. 
For reasons which are as yet unclear, females are more susceptible to the development of 
anti-Fs [113]. Among our study subjects, there are only 6 females with a history of 
pregnancy, 2 females with a history of blood transfusion and 18 were exposed to surgery 
or medical operations. In contrast, one male has a history of blood transfusion and 24 
were exposed to surgery or medical operations. Additionally, women in general have a 
stronger immune system/ responses than men. This gender difference is believed to be 
controlled by differences in the blood levels of gonadal steroid hormones including the 
female hormone, estrogen, which stimulates immune responses, and the male hormone, 
testosterone, which has an immunosuppressive effect [113]. In Tarlach (2013) study, they 
isolated a cluster of genes regulated by testosterone and also associated with the amount 
of antibodies and cytokines produced. The researchers found that male participants with 
the highest levels of the hormone testosterone had the lowest antibody response  [114]. 
 
The anti-Fs frequency also showed variations in Igs classes, among blood groups, 
although Young (1979), previousely indicated that presence of Fs antibodies in sera is 
independent of blood group type [53]. Furthermore, the highest frequency of subjects 
lacking anti-Fs antibodies was among AB blood group, where 13.6% of AB individuals 
and 1.4% of all individuals were found to lack Fs antibodies.  These results may be 
partially explained by the fact that  individuals who lack naturally occurring anti-A and 
anti-B has also less anti-Fs present, but more convincing reasons are yet to be uncovered.  
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Stronger reaction was shown in our study in IgG test compared to IgM.  Humphrey and 
Dourmashkin (1965) observed that with sheep RBCs, the maximum number of anti-Fs 
antibody molecules that will bind to respective FORS antigens is about 600 000 for IgG 
and 120 000 for IgM [115]. Thus, FORS antigen binds fewer IgM molecules compared to 
IgG molecules. The explanation for such finding could be that the antigen sites are so 
closely packed that, at saturation, IgG molecules cover the whole surface; while the IgM 
molecules are much larger, and thus the maximum number that could bind would clearly 
be less [116]. 
 
In addition, weaker reactions with IgG and IgM anti-Fs was seen in B blood group among 
our donors.  This result contradicts with Hirayama et al. (1989) study, which showed 
higher titer of Fs antibodies in blood group AB than other blood groups.  
 
4.3   GBGT1 sequencing 
 
Multi-step glycosylation are required for biosynthesis of FORS antigen and deficiency or 
defect in any step may result in the failure to synthesize this antigen. For the FORS1 
antigen negativity in humans we assumed that different missense mutations might be 
responsible in addition to the previous discovered mutations. To identify them, we did 
sequence analysis of the specific part of GBGT1 gene. GBGT1- likes ABO gene consists 
of seven exons, with most of the coding sequence localized in exon 7. Thus, we have 
screened exon 7 partially by DNA sequencing to detect the two most common mutations 
responsible for the FORS1 antigen negativity.  
 
Our results are consistent with previous studies that humans usually do not express the 
FORS1 antigen. Previous published studies have shown that FORS1 antigen expression 
in human is very rare, due to many missense mutations that affect its catalytic domain 
encoded by exon 7 of GBGT1 gene which disturb Fs synthetase and inactivate it. The 
most important mutations are c.688G>A [p.Gly230Ser] and c.887A>G [p.Gln296Arg]). 
76 
 
These glycine and glutamine residues are conserved among functional GBGT1 genes in 
FORS1 antigen positive species [19]. 
 
 In this study, we found the inactivating missense mutation Q296R present in all study 
subjects, which in turn confirms the FORS1 antigen negativity determined by serological 
testing. In addition, we found other missense and coding-synonymous polymorphisms. 
All these polymorphisms were found in the heterozygote state except one, c.870C>T p. 
(G290G) that was found in the homozygote state in one subject. On the other hand, we 
found these polymorphisms in unrelated subjects (all the study participants were from 
unrelated families). 
  
Most alleles coding for most blood group antigens result from SNPs encoding amino acid 
substitutions in either a glycosyltransferase or extracellular domain of a red cell 
membrane protein. The allele frequency for the c.870 C>T (G290G) and c.696 C>T 
(Y232Y) variants detected among our Palestinian subjects, were 3.6% and 0.5% 
respectively, which were lower than the frequency of these alleles reported in Exome 
Variant Server (allele frequency reported for African Americans and European 
Americans), viz., 6.7% and 3%, respectively [117]. While the allele frequency of the 
c.728 G>A (R243H) variant was 1% among our Palestinian subjects and was higher than 
the frequency reported in the Exome Variant Server, viz., 0.008% [117].  
 
The R243H has a damaging effect on the GBGT1 gene product if it occurs apart from the 
two known mutations for FORS1 antigen negativity in humans, as predicted by 
PolyPhen-2 software. Of the aforementioned three SNPs, only the G290G SNP was 
detected in a two Swedish subjects and in a single Portuguese subject. The variation in 
allele frequency observed between Palestinian subjects and that reported in EVS probably 
reflects the genetic variations among different populations. Concerning the Swedish and 
Portuguese subjects, the sample number included in this study is small and probably and 
cannot be used to deduce any conclusion about the allele frequency in these populations. 
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The SNPc.727C→T p. (R243C) is a novel mutation and was detected in one Palestinian 
subject (allele frequency 0.2%) and has not been reported earlier. This SNP has a 
damaging effect on the GBGT1 gene product if it occurs apart from the two known 
mutations for FORS1 antigen negativity in humans, as predicted by PolyPhen-2 software. 
This SNP was not detected in any of the Swedish or Portuguese subjects included in this 
study.  
 
Taken together, the DNA analysis of exon 7 of the GBGT1 gene revealed that FORS1 
antigen negativity in our study subjects from three different populations is most probably 
caused by the Q296R mutation which has been earlier reported in as the cause for Fs 
α1.3-GalNac transferase synthetase inactivation in other populations [12]. Also another 
two mutations R243H and R243C has been detected in a small number of our study 
subjects and can cause inactivation of Fs α1, 3-GalNac transferase when they occur in 
apart from the Q296R mutations. Since the Q296R mutation is almost ubiquitous in 
humans, it seems that the R243H and R243C have occurred after the Q296R mutation.   
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4.4   Conclusion  
 
All study populations included in this study were negative for the FORS1 antigen by 
forward grouping of RBCs and DNA analysis. Naturally occurring anti-Fs antibodies are 
present in the serum of majority of study donors (96.2 %), they are predominantly IgM. 
DNA sequencing supports FORS1 negativity in our samples. Alignment of generated 
sequence with GBGT1gene reference sequence confirmed the presence of 887A>G 
[p.Gln296Arg] and 688G>A [p.Gly230Ser] mutations. For c.727C→T p. (R243C) SNP, 
a novel missense mutation was detected in a Palestinian subject and has a damaging 
effect on Fs synthetase. 
Overall, the results of our study indicated that the prevalence of FORS blood group 
system is low at least among our studied populations.  Nonetheless, care must be taken 
when interpreting the results especially when dealing with such very low frequency 
antigens in multiple transfusion patients. To date, our experience with FORS 
antigen/antibodies tests as a method for FORS1 antigen detection suggests that serology 
should still be complemented by GBGT1 gene sequencing.  
Finally, further studies are needed to investigate the association between FORS1 antigen 
and or Fs antibody and physiological or pathological processes. Also further 
investigations are needed to further improve the Kodecyte system for testing for anti-Fs 
antibodies and explore its use as a screening method for certain tumors.  
 
4.5   Weaknesses or limitations in the current study plan 
 
Full gene sequencing of GBGT1 using 7 primer pairs has the ability to provide additional 
information regarding FORS1 human negativity and to reveal all possible or novel 
mutations when compared to targeted genotyping approaches.  
 
The sample size of subjects from each target population was not representative to the 
respective population. Our data also used a limited genotyping samples based on 
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ethnicity, and cannot detect all polymorphisms carriers in all populations. Most 
genotyping of our samples are based on Palestinian population and small sample volume 
from Sweden and Portugal. We might assume that different populations could have 
different results regarding presence/absence of FORS system and GBGT1 genotyping. 
 
For anti-Fs antibodies testing, we wanted to replace the sheep RBCs by synthetic RBC 
Function-spacer-lipid (FSL) constructs which is supplied by KODE Biotech Materials 
(Auckland, New Zealand), but they were not suitable for all negative controls.  
 
4.6  Recommendations 
 
Now, much research has focused on the challenges facing the tissue and organ 
transplantation such as unavailability of acceptable human donor organs, the low rate of 
long term success and the serious risks of infection and cancer. In that field, normal and 
cancer tissues FORS expression research are needed, because certain normal tissues and 
malignancies in humans have been shown to express this particular antigen.  
  
In addition, our data prompted us to reinvestigate the full gene sequencing in large 
screening population samples to detect many variants, some of them known to be 
common, some rare and some not yet described. We need also to modify synthetic Fs and 
FSL- kodecyte construct for anti-Fs testing as new technology and more specific method.  
 
So, further studies will be needed to completely understand FORS blood group system as 
an area of interest, since having positive FORS1 RBCs would be problematic in blood 
transfusion and transplantation. 
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Appendix B 
Palestinian donor’s characterizations  
 No. 
 
 
Sex 
 
 
Age 
 
 
College 
 
 
Residence 
place 
 
 
received 
blood 
transfusion 
 
surgery or 
medical 
operation 
before 
chronic or 
hereditary 
diseases 
 
ABO 
group 
 
Rh(D) 
  
 
1  M 21 Health Professions Hebron No no No AB positive 
2 M 23 Health Professions Qalqelia No no No O positive 
18 M 21 Health Professions Hebron No no No AB positive 
19 F 18 Health Professions Ramallah No no No B positive 
20 F 18 Health Profession Jerusalem No no No A positive 
21 F 18 Health Professions Hebron No no No O Positive 
22 F 18 Health Professions Hebron No no No O Positive 
23 F 21 
Al-Quds Bard for Arts & 
Sciences Ramallah No no No A Positive 
24 F 20 
Al-Quds Bard for Arts & 
Sciences Hebron No no No A Positive 
25 M 23 
Al-Quds Bard for Arts & 
Sciences Bethlehem No no No O Positive 
26 M 23 
Al-Quds Bard for Arts & 
Sciences Ramallah No no No O Positive 
27 F 20 
Al-Quds Bard for Arts & 
Sciences Nablus No no No B Positive 
28 F 19 Health Professions Bethlehem No Yes No A Positive 
29 F 19 Health Professions Ramallah No no No AB Positive 
30 F 21 Arts Al-Ezaria No no No A Positive 
31 F 21 Arts Abu Dis No no No O Positive 
32 F 18 Health Professions Abu Dis No no No B Positive 
33 F 18 Health Professions Abu Dis No no No O Positive 
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34 F 18 Arts Al-Ezaria No no No O Positive 
35 F 21 Educational Science Hebron No Yes No O Positive 
36 F 21 Educational Science Hebron No no No O Positive 
37 F 20 Arts Bethlehem No no No A Positive 
38 M 19 Dentistry Ramallah No no No A Positive 
39 M 20 Dentistry Ramallah No no No O Positive 
40 M 22 Pharmacy Hebron No no No O Positive 
41 M 21 Pharmacy Bethlehem No no No O Positive 
42 M 23 Pharmacy Hebron No no No O Positive 
43 M 23 Arts Bethlehem No no No A Positive 
44 M 24 Business & Economics Hebron No Yes No AB Positive 
45 F 21 Pharmacy Nablus No no No AB Positive 
46 F 21 Pharmacy Hebron No no No A Positive 
47 F 20 Dentistry Bethlehem No no No B Positive 
48 F 21 Pharmacy Ramallah No no No A Positive 
49 M 19 Business & Economics Hebron No no No A Positive 
50 M 20 Science & Technology Hebron No no No A Negative 
51 M 19 Business & Economics Ramallah No Yes No O Positive 
52 M 24 Business & Economics Hebron No no No O Positive 
53 M 18 Business & Economics Hebron No no No B Negative 
54 M 18 Arts Hebron No no No A Positive 
55 M 21 Arts Bethlehem No no No AB Positive 
56 M 20 Arts Abu Dis No no Yes B Positive 
57 M 21 Science & Technology Bethlehem No no No B Positive 
58 M 22 Arts Bethlehem No no No AB Negative 
59 M 20 Business & Economics Ramallah No no No A Positive 
60 M 18 Business & Economics Bethlehem No Yes No O Positive 
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61 F 18 Business & Economics Hebron No no No A Positive 
62 F 18 Business & Economics Hebron No no No A positive 
63 M 20 Law Ramallah No no No O positive 
64 M 20 Law Jerusalem No no No AB positive 
65 M 23 Law Ramallah No no No A Negative 
66 M 21 Law Nablus No Yes No B positive 
67 M 19 Law Nablus No no No A positive 
68 M 18 Law Ramallah No no No O positive 
69 M 21 Law Ramallah No no No AB positive 
70 F 19 Medicine  Hebron No no No O positive 
71 F 19 Engineering Ramallah No no No B positive 
72 F 19 Medicine  Hebron No no No O positive 
73 F 19 Medicine  Hebron No Yes No A positive 
74 M 21 Science & Technology Bethlehem No Yes No A positive 
75 M 18 Medicine  Nablus No no No A positive 
76 F 19 Medicine  Al-Naserah No no No o positive 
77 F 18 Medicine  Hebron No no No A positive 
78 F 18 Medicine  Jerusalem No Yes No AB positive 
79 F 19 Dentistry Nablus No no No O positive 
80 F 21 Arts Jericho No no No A positive 
81 F 19 Arts Jericho No Yes No A positive 
82 F 19 Pharmacy Jericho No no No O positive 
83 F 19 Dentistry Hebron Yes no No B Negative 
84 F 19 Law Hebron No no No O positive 
85 M 18 Medicine  Abu Dis No Yes No A positive 
86 F 19 Dentistry Qalqelia No no No o positive 
87 M 21 Dentistry Nablus No Yes No AB positive 
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88 M 23 Medicine Abu Dis No no No O Positive 
89 M 24 Medicine Jerusalem No Yes No A Positive 
90 M 22 Medicine Nablus No no No O positive 
91 M 21 Arts Hebron No Yes No A positive 
92 M 20 Arts Jenin No no No A positive 
93 M 23 Arts Abu Dis No no No A positive 
94 M 22 Arts Jericho No no No B Negative 
95 M 22 Arts Ramallah No no No A positive 
96 F 19 Arts Bethlehem No Yes No A positive 
97 F 19 Arts Bethlehem No no No B positive 
98 M 23 Arts Hebron No no No O positive 
99 M 18 Arts Hebron No no No B positive 
100 F 18 Educational Science Al-Ezaria No no No B positive 
101 M 22 Arts Nablus No no No O positive 
102 F 22 Arts Jerusalem Yes no No B positive 
103 F 20 Arts Abu Dis No Yes No B Negative 
104 F 19 Business & Economics Ramallah No no No O Negative 
105 F 20 Science & Technology Nablus No Yes No O positive 
106 F 19 Science & Technology Ramallah No no No AB positive 
107 M 20 Business & Economics Ramallah No no No AB positive 
108 M 20 Business & Economics Ramallah No no No O Negative 
109 M 22 Arts Hebron No Yes No A positive 
110 M 20 Science & Technology Al-Ezaria No no No O positive 
111 F 18 Arts Ramallah No no No A positive 
112 M 21 Engineering Hebron No no No A positive 
113 F 18 Business & Economics Ramallah No Yes No B positive 
114 M 19 Arts Hebron No no No A positive 
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115 M 21 Engineering Ramallah No no No O positive 
116 F 21 Science & Technology Jerusalem No no No A positive 
117 F 20 Science & Technology Jerusalem No no No A positive 
118 M 22 Arts Hebron No Yes No A positive 
119 M 19 Dentistry Ramallah No no No O Negative 
120 M 18 Dentistry Ramallah No no No AB positive 
121 M 18 Engineering Tulkarm No no No A positive 
122 F 21 Arts Jericho No no No A positive 
123 F 21 Arts Ramallah No Yes No O positive 
124 M 26 Arts Ramallah No no No B positive 
125 M 26 Arts Hebron No no No O positive 
126 M 23 Educational Science Abu Dis No no No O positive 
127 M 22 Educational Science Jerusalem Yes Yes No A positive 
128 F 22 Arts Jerusalem No no No B positive 
129 F 19 Arts Jericho No no Yes A positive 
130 F 20 Arts Jerusalem No no No A positive 
131 F 19 Arts Ramallah No no No A positive 
132 F 21 Da’wa &Islamic studies Ramallah No no No O positive 
133 F 20 Business & Economics Jerusalem No Yes Yes O positive 
134 F 20 Engineering Ramallah No no No AB positive 
135 F 20 Engineering Bethlehem No no No A Negative 
136 F 20 Engineering Bethlehem No no No B positive 
137 F 20 Engineering Bethlehem No no No AB positive 
138 F 20 Engineering Bethlehem No no No A Positive 
139 M 23 Law Hebron No no No A Negative 
140 M 21 Law Jericho No Yes No B positive 
141 M 22 Law Hebron No no No B positive 
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142 F 20 Business & Economics Ramallah No no No A positive 
143 F 20 Business & Economics Jerusalem No no No O positive 
144 F 22 Law Bethlehem No no No A positive 
145 F 20 Business & Economics Ramallah No Yes No A positive 
146 F 21 Business & Economics Ramallah No no No B positive 
147 M 18 Pharmacy Ramallah No Yes No A positive 
148 M 19 Engineering Bethlehem No no No O positive 
149 M 20 Law Hebron No no No AB positive 
150 M 21 Da’wa &Islamic studies Hebron No  no No O positive 
151 M 24 Business & Economics Hebron No no No O positive 
152 M 19 Health Professions Hebron No no No AB positive 
153 M 20 Health Professions Hebron No no No O positive 
154 F 18 Dentistry Jerusalem No no No O positive 
155 M 19 Health Professions Hebron No no No O positive 
156 F 19 Law Jerusalem No no No A positive 
157 F 19 Arts Abu Dis No no No A positive 
158 M 19 Law Al-Ezaria No Yes No B positive 
159 M 25 Science & Technology Nablus No no No A positive 
160 F 18 Science & Technology Nablus No no No O positive 
161 M 23 Law Jerusalem No no No B positive 
162 F 21 Dentistry Hebron No no No B positive 
163 F 21 Dentistry Tulkarm No Yes No O positive 
164 M 22 Health Professions Hebron No no No B positive 
165 F 19 Law Ramallah No Yes Yes O positive 
166 F 20 Law Bethlehem No no No B positive 
167 F 23 Law Hebron No no No O positive 
168 F 19 Law Hebron No no No A Negative 
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169 M 18 Law Hebron No no No O positive 
170 M 20 Medicine Hebron No Yes No O positive 
171 M 19 Dentistry Nablus No no No A positive 
172 M 19 Dentistry Hebron No Yes No O positive 
173 M 20 Dentistry Hebron No no No O positive 
174 M 23 Science & Technology Ramallah No no No B positive 
175 M 21 Science & Technology Ramallah No Yes Yes A Negative 
176 M 20 Arts Nablus No no Yes O positive 
177 M 18 Educational Science Bethlehem No no No B Negative 
178 M 22 Dentistry Tulkarm No Yes No A positive 
179 M 26 Arts Bethlehem No no No B positive 
180 M 24 Medicine Hebron No Yes No O positive 
181 M 23 Medicine Hebron No no No A positive 
182 M 23 Medicine Hebron No no No O positive 
183 M 19 Law Hebron No no No A positive 
184 M 21 Law Ramallah No no No B positive 
185 M 23 Arts Bethlehem No no No AB positive 
186 F 21 Arts Jerusalem No Yes No O positive 
187 M 20 Da’wa &Islamic studies Jerusalem No no No A positive 
188 F 19 Science & Technology Jerusalem No Yes No B positive 
189 M 25 Engineering Hebron No no No AB positive 
190 M 19 Business & Economics Ramallah No Yes No A positive 
191 F 20 Law Tulkarm No no No O positive 
192 F 20 Law Ramallah No no No O positive 
193 F 30 Arts Hebron No no No A positive 
194 F 37 Law Hebron No no No AB positive 
195 F 26 Law Al-Ezaria No no No A positive 
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196 M 33 Engineering Hebron No no No O positive 
197 F 19 Health Professions Hebron No no No A positive 
198 F 19 Health Professions Hebron No no No A positive 
199 F 21 Health Professions Ramallah No no No O positive 
200 F 20 Health Professions Ramallah No no No B positive 
201 F 21 Law Hebron No Yes No O positive 
202 F 18 Law Ramallah No Yes No O positive 
203 F 26 Arts Jerusalem No no No O Negative 
204 F 19 Law Jerusalem No no No B positive 
205 F 18 Educational Science Hebron No no No O positive 
206 F 19 Law Hebron No no No A positive 
207 F 24 Law Hebron No no No A Negative 
208 F 18 Law Hebron No no No A positive 
209 F 22 Law Bethlehem No no No A positive 
210 F 18 Da’wa &Islamic studies Hebron No no No A positive 
211 F 18 Educational Science Hebron No no No B positive 
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Appendix C 
Population study-Palestine 
Collection of Study sample: A convenient sample with a total of 211 samples will be 
collected from all colleges of Al-Quds University at Abu-Dies campus. The distribution 
of study sample among the colleges is shown in the table. 
 
 
 
Collage name 
 
No. of students 
per college* 
Study sample 
 
No. of samples to be 
collected from 
college 
No. of 
Males 
No. of 
Females  
Arts 2183 46 24 22 
Da’wa &Islamic studies 188 4 2 2 
Health Professions 955 30 15 15 
Engineering 531 12 6 6 
Science & Technology 592 13 7 6 
Pharmacy 357 8 4 4 
Business & Economics 817 20 10 10 
Medicine  580 15 9 6 
Dentistry 583 16 9 7 
Law 1546 34 17 17 
Educational Sciences 371 8 4 4 
Al-Quds Bard for Arts & Sciences 211 5 2 3 
 
Total  
 
8914 
 
211 
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*The number of students per each college as for the Fall Semester 2014-2015. 
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Appendix D 
Study Questionnaire/ English 
 
Sample #: ………. 
Investigation of Forssmann antigen in a cohort of Palestinian and Swedish 
population  
Dear Student: We are conducting a research project to investigate Forssman antigen 
among Palestinian population. This study aims to investigate this antigen in a cohort of 
Palestinian subjects and to determine the genetic mutations causing Forssman antigen 
negativity among the study subjects. 
Therefore, we kindly ask you to participate in this study by providing the information 
necessary to fill out this questionnaire and to donate 5 ml of blood. The results of the 
study will be used for purpose of scientific research only.  
Researcher: Wafa’ Abu-Siba’ 
.....................................................................................................................  
 Gender:              Male             Female 
 Age :  …….       years 
 College… 
 Residence place… 
 Have you received blood transfusion in the past three months?  Yes    No 
 For married females: have you ever been pregnant before?   Yes     No 
 Have you ever done a surgery or medical operation before?  Yes    No 
 Do you suffer from any chronic or hereditary diseases?   Yes    No 
 If your answer for the previous question is yes, please specify the disease 
……………………….. 
 Do you know your blood group (ABO/Rh)?  Yes           No 
 If you know your blood group, specify it: ……………………………  
  ………………  ..................................................................... .............................................. 
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Consent form: 
Here I certify that I have voluntarily participated in this study by filling up this 
questionnaire and donating a blood sample and authorize the researcher to use the above 
data and blood sample for scientific research only.    
Signature:                                                                             Date:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 801
 
 
                        cibarA/eriannoitseuQ ydutS
 رﻗم اﻟﻌﯾﻧﺔ: ..…………
 اﺳﺗﺑﺎﻧﺔ
 namssroF أﺧﻲ اﻟﻄﺎﻟﺐ /أﺧﺘﻲ اﻟﻄﺎﻟﺒﺔ: ﻧﻘﻮم ﻓﻲ ﺟﺎﻣﻌﺔ اﻟﻘﺪس ﺑﺠﻤﻊ ﻋﯿﻨﺎت ﻷﺟﻞ ﻋﻤﻞ دراﺳﺔ ﻣﺎﺟﺴﺘﯿﺮ ﺣﻮل 
وﻗﺪ اﺧﺘﺮﻧﺎ ﻋﯿﻨﺔ   ,وﻣﻌﺮﻓﺔ ﻧﺴﺒﺔ وﺟﻮد ھﺬا اﻷﻧﺘﯿﺠﻦ ﻓﻲ ﻓﻠﺴﻄﯿﻦ  واﻟﻄﻔﺮات اﻟﻮراﺛﯿﺔ اﻟﻤﺘﻌﻠﻘﺔ ﺑﮫ (    ) negitnA
  .ﻢ ﻣﻞء ھﺬه اﻻﺳﺘﺒﺎﻧﺔ, راﺟﯿﻦ ﻣﻨﻜﻷﺟﻞ ھﺬا اﻟﻐﺮض ﻋﺸﻮاﺋﯿﺔ ﻣﻦ طﻼب اﻟﺠﺎﻣﻌﺔ 
  ﺷﺎﻛﺮﯾﻦ ﻟﻜﻢ ﺣﺴﻦ ﺗﻌﺎوﻧﻜﻢو
  ......................................................................................................
 اﻟﺟﻧس:        ذﻛر            أﻧﺛﻰ
 اﻟﻌﻣر:           ﺳﻧﺔ
 اﻟﻛﻠﯾﺔ:
 ﻣﻛﺎن اﻻﻗﺎﻣﺔ :
  ﻓﻲ اﻟﺛﻼث ﺷﮭور اﻟﻣﺎﺿﯾﺔ   ﻧﻌم        ﻻھل ﺳﺑﻖ وأن اﺣﺗﺟت إﻟﻰ وﺣدة دم 
 ﻟﻠطﺎﻟﺑﺎت اﻟﻣﺗزوﺟﺎت : ھل ﺳﺑﻖ وﻛﻧت ﺣﺎﻣل                     ﻧﻌم        ﻻ
 ھل ﺳﺑﻖ وأﺟري ﻟك ﻋﻣﻠﯾﺔ ﺟراﺣﯾﺔ                               ﻧﻌم        ﻻ
 ھل ﺗﻌﺎﻧﻲ ﻣن أي ﻣرض ﻣزﻣن                                    ﻧﻌم         ﻻ
 ھل ﺗﻌرف ﻓﺻﯾﻠﺔ دﻣك                                            ﻧﻌم          ﻻ
  ﻣﺎھﻲ :          
 .......................................................................................................................
ن ﯾﺳﺗﻌﻣل ﯾرد ﻓﻲ ھذه اﻻﺳﺗﺑﺎﻧﺔ ﻣن ﻣﻌﻠوﻣﺎت ﺳﯾﺣﻔظ ﺑﺳرﯾﺔ ﺗﺎﻣﺔ وﻟأﻗر أن اﻟﻌﯾﻧﺎت اﻟﺗﻲ ﺳﯾﺗم ﺳﺣﺑﮭﺎ وﻛذﻟك ﻣﺎ 
   إﻻ ﻷﻏراض اﻟﺑﺣث اﻟﻌﻠﻣﻲ                                        اﻟطﺎﻟﺑﺔ : وﻓﺎء أﺑو اﻟﺳﺑﺎع 
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Appendix E 
Swedish DNA extraction protocole  
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Appendix F 
 
Portuguese DNA extraction protocol 
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  ﻧﯾﯾنﺑﺣث وﺟود اﻟﻣﺳﺗﺿد ﻓورﺳﻣﺎن ﻓﻲ ﻛرﯾﺎت اﻟدم اﻟﺣﻣراء ﺑﯾن اﻟﺳﻛﺎن اﻟﻔﻠﺳطﯾ
 اﻋﺪاد :  وﻓﺎء ﻋﻠﻲ ﻋﺒﺪاﻟﻤﻨﻌﻢ اﺑﻮﺳﺒﺎع
 ﻣﺸﺮف اول :  د. ﻣﺤﻤﻮد ﻋﺒﺪ ﺳﺮور 
 ﻣﺸﺮف ﺛﺎن : د. ﻛﺎﻣﯿﻼ ھﯿﺲ
 
 اﻟﻤﻠﺨﺺ
( ﻣﺆﺧﺮا ﻓﻲ اﻷﻧﺴﺠﺔ اﻟﻤﻜﻮﻧﺔ ﻟﺨﻼﯾﺎ دم اﻹﻧﺴﺎن اﻟﻄﺒﯿﻌﯿﺔ ، وﺑﺎﻟﺘﺎﻟﻲ ﺗﻢ  1SROFُوﺻﻒ اﻷﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ) ﻣﻘﺪﻣﺔ :
  . 13ts( ﻛﺄﺣﺪ أﻧﻈﻤﺔ اﻟﺪم وﯾﺤﻤﻞ رﻗﻢ ﻧﻈﺎم اﻟﺪم  SROFاﻟﺘﻌﺮف ﻋﻠﻰ ﻓﻮرس ) 
ﻓﻲ ﻛﺮﯾﺎت اﻟﺪم اﻟﺤﻤﺮاء ﻓﻲ اﻻﻧﺴﺎن وﺗﻤﯿﯿﺰ اﻻﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﮫ ﺑﯿﻦ  1ﻟﻠﺒﺤﺚ ﺣﻮل ﺗﻌﺒﯿﺮ اﻟﻤﺴﺘﻀﺪ ﻓﻮرس اﻷھﺪاف :
 ﯿﻦ وﻣﻘﺎرﻧﺔ ذﻟﻚ ﻣﻊ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻟﺴﻜﺎن اﻻوروﺑﯿﯿﻦ.اﻟﺴﻜﺎن اﻟﻔﻠﺴﻄﯿﻨﯿ
ﻓﺮداً ﻣﻦ أوروﺑﺎ ،  56ﻣﻦ ﻓﻠﺴﻄﯿﻦ وﻛﺬﻟﻚ   ﻣﻮﻟﻮدا ﺟﺪﯾﺪاً  37ﻓﺮداً ﺑﺎﻟﻐﺎ و 112ﺷﻤﻠﺖ ھﺬه اﻟﺪراﺳﺔ  اﻟﻄﺮق واﻟﻤﻮاد : 
ﺣﯿﺚ ﺗﻢ ﻓﺤﺺ ﻛﺮﯾﺎت اﻟﺪم اﻟﺤﻤﺮاء ﻟﮭﺆﻻء اﻷﻓﺮاد ﻟﻮﺟﻮد اﻷﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ﺑﺎﺳﺘﺨﺪام اﻷﺟﺴﺎم اﻟﻤﻀﺎدة اﻟﻮﺣﯿﺪة 
(، وﻛﺬﻟﻚ ﺗﻢ ﻓﺤﺺ اﻟﺒﻼزﻣﺎ ﻟﻮﺟﻮد اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻸﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ﺑﺎﺳﺘﺤﺪام  )sF-itna lanolconomﻨﺴﻠﯿﺔ  اﻟ
ﻛﺮﯾﺎت اﻟﺪم اﻟﺤﻤﺮاء ﻟﻸﻏﻨﺎم ، وأﯾﻀﺎ ﺗﻢ اﻟﺘﺤﻘﻖ ﻣﻦ اﻟﺒﯿﻮﻟﻮﺟﯿﺎ اﻟﺠﺰﯾﺌﯿﺔ ﻟﮭﺬا اﻷﻧﺘﺠﯿﻦ ﻋﻦ طﺮﯾﻖ ﻋﻤﻞ ﺗﺴﻠﺴﻞ ﻟﻠﺤﻤﺾ 
ﻓﯿﺤﻔّﺰ اﻟﺨﻄﻮة اﻟﻨﮭﺎﺋﯿﺔ ﻓﻲ   esatehtnys-sF ﻸﻧﺰﯾﻢواﻟﺬي ﯾﻌﻤﻞ ﺗﺮﻣﯿﺰا ﻟ  1TGBGﻟﻠﺠﯿﻦ  7اﻟﻨﻮوي ﻣﻦ اﻛﺴﻮن 
  ( .  1SROFﺗﺼﻨﯿﻊ اﻷﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن )
ﺟﻤﯿﻊ ﻋﯿﻨﺎت اﻟﺪراﺳﺔ ﻛﺎﻧﺖ ﺳﻠﺒﯿﺔ ﻟﻮﺟﻮد اﻷﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ﺑﺎﺳﺘﺨﺪام اﻟﻜﺸﻒ اﻟﻤﺼﻠﻲ ، اﻷﺟﺴﺎم اﻟﻤﻀﺎدة   اﻟﻨﺘﺎﺋﺞ :
ﻣﻦ ﻋﯿﻨﺎت اﻟﺪراﺳﺔ ، وﻛﺎن ﻏﯿﺎب ھﺬه اﻷﺟﺴﺎم  %2.69وﺟﺪت ﻓﻲ   MgIو   GgIﻟﻼﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ﺑﻨﻮﻋﯿﮭﺎ 
اﻟﻤﻀﺎدة ﺑﻨﻮﻋﯿﮭﺎ أﻛﺜﺮ ﺷﯿﻮﻋﺎ ﺑﯿﻦ اﻟﺬﻛﻮر ﻣﻘﺎرﻧﺔ ﺑﺎﻻﻧﺎث ، واﻟﺘﻔﺎﻋﻞ اﻷﻗﻮى ﻟﻮﺣﻆ أﯾﻀﺎ ﻓﻲ اﻻﻧﺎث ، ﺑﺎﻟﻨﺴﺒﺔ ﻟﻔﺼﺎﺋﻞ 
ﺋﻞ اﻟﺪم وﺟﻮده ﻓﻲ ﻓﺼﺎ ﻟﻮﺣﻆ MgIأو   GgI( ﻟﻸﺟﺴﺎم اﻟﻤﻀﺎدة ﺳﻮاء  4و + 3اﻟﺪم : ﻛﺎن اﻟﺘﻔﺎﻋﻞ اﻷﻗﻮى )درﺟﺔ +
ﻋﻠﻰ اﻟﺘﻮاﻟﻲ ( ﻣﻘﺎرﻧﺔ ﻣﻊ ﻓﺼﺎﺋﻞ اﻟﺪم اﻷﺧﺮى ، وﻛﺎﻧﺖ أﻋﻠﻰ ﻧﺴﺒﺔ ﻟﺴﻠﺒﯿﺔ اﻷﺟﺴﺎم  %6.05و  %05) Oو  A
ﻓﻲ ﺟﻤﯿﻊ أﻓﺮاد  %40.1و  BAﻓﻲ اﻷﻓﺮاد اﻟﺬﯾﻦ ﯾﺤﻤﻠﻮن ﻓﺼﯿﻠﺔ اﻟﺪم  %6.31) ﻛﺎﻧﺖ  BAاﻟﻤﻀﺎدة ﻓﻲ ﻓﺼﯿﻠﺔ اﻟﺪم 
  اﻟﺪراﺳﺔ .
ﻓﻘﺪ ﻛﺎﻧﺖ ﺟﻤﯿﻊ اﻟﻌﯿﻨﺎت ﺗﺤﻤﻞ اﻟﻄﻔﺮﺗﯿﻦ اﻟﻮراﺛﺘﯿﻦ  1TGBGﻟﻠﺠﯿﻦ  7ﺑﺎﻟﻨﺴﺒﺔ ﻟﺘﺴﻠﺴﻞ اﻟﺤﻤﺾ اﻟﻨﻮوري ﻣﻦ اﻛﺴﻮن 
( اﻟﺘﻲ ُأﺑﻠﻎ ﻋﻨﮭﺎ ﺳﺎﺑﻘﺎ ﻟﺘﻜﻮن ﻣﺴﺆوﻟﺔ ﻋﻦ ﺳﻠﺒﯿﺔ  ]reS032ylG.p[ A>G886 و grA692nlG.p[ G>A788)
)اﺧﺘﻼف اﻷﺷﻜﺎل ﻓﻲ ﻧﯿﻮﻛﻠﯿﻮﺗﯿﺪة  PNSاﻷﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ﻓﻲ اﻻﻧﺴﺎن ، ﺑﺎﻻﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ﺗﻢ اﻟﻜﺸﻒ ﻋﻦ أرﺑﻊ 
. واﺣﺪة ﻣﻦ  %6.3إﻟﻰ  %2.0د ﻟﻸﻟَﯿﻞ ﯾﺘﺮاوح ﺑﯿﻦ ﻣﻨﮭﻢ طﻔﺮﺗﯿﻦ ﺻﺎﻣﺘﺘﯿﻦ وطﻔﺮﺗﯿﻦ ﻣﻐﻠﻄﺘﯿﻦ ﻣﻊ ﺗﺮدّ واﺣﺪة ( ، ﻛﺎﻧﺖ 
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ﻋﯿﻨﺎت اﻟﺪراﺳﺔ ، ھﺬه اﻟﻄﻔﺮة ﻟﮭﺎ ﺗﺄﺛﯿﺮ  ﻓﻲ أﻧﺜﻰ ﻓﻠﺴﻄﯿﻨﯿﺔ ﻣﻦ ( ﻛﺎﻧﺖ ﺟﺪﯾﺪة ووﺟﺪت  C3442Rاﻟﻄﻔﺮات اﻟﻤﻐﻠﻄﺔ )
، أﯾﻀﺎ ﻟﻢ ﯾﻜﻦ ھﻨﺎك ﻓﺮق ﻛﺒﯿﺮ   2 nehPyloP( ﻛﻤﺎ ﻛﺎن ﻣﺘﻮﻗﻌﺎ ﻣﻦ ﻗﺒﻞ ﺑﺮﻧﺎﻣﺞ esatehtnys sFﺿﺎر ﻋﻠﻰ أﻧﺰﯾﻢ ) 
( وﺗﻌﺪد اﻷﺷﻜﺎل اﻟﺠﯿﻨﯿﺔ ﻟﻠﺠﯿﻦ  334.0=pو   804.0=pﺑﯿﻦ وﺟﻮد أو ﻏﯿﺎب اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻸﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ) 
  . 1TGBG
ﺑﺸﻜﻞ ﻋﺎم ﻧﺘﺎﺋﺠﻨﺎ ﻟﮭﺬه اﻟﺪراﺳﺔ  ﻧﻈﺎم ﻓﺼﯿﻠﺔ اﻟﺪم ﻓﻲ ﻓﻠﺴﻄﯿﻦ SROFھﺬه ھﻲ اﻟﺪراﺳﺔ اﻷوﻟﻰ ﻟﻠﺘﺤﻘﯿﻖ اﻻﺳﺘﻨﺘﺎج : 
ﻓﻲ اﻟﺴﻜﺎن اﻟﺬﯾﻦ ﺷﻤﻠﺘﮭﻢ اﻟﺪراﺳﺔ ، ﻛﺬﻟﻚ  ﻋﻠﻰ اﻻﻗﻞ ھﻮ ﻧﻈﺎم ﻣﻨﺨﻔﺾ اﻻﻧﺘﺸﺎر  SROFإﻟﻰ أن ﻧﻈﺎم اﻟﺪم  ﺗﺸﯿﺮ
ﻛﻤﺎ ﺗﻢ اﻛﺘﺸﺎف طﻔﺮة  . ﻞ ﻏﺎﻟﺒﯿﺔ اﻟﺒﺸﺮ اﻷﺻﺤﺎء اﻟﺒﺎﻟﻐﯿﻦاﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻸﻧﺘﺠﯿﻦ ﻓﻮرﺳﻤﺎن ھﻲ ﻣﻮﺟﻮدة ﻓﻲ ﻣﺼ
  . esatehtnys-sFن ﻟﮭﺎ ﺗﺄﺛﯿﺮ ﺿﺎر ﻋﻠﻰ اﻷﻧﺰﯾﻢ ﻓﻲ واﺣﺪة ﻣﻦ اﻟﻌﯿﻨﺎت اﻟﻔﻠﺴﻄﯿﻨﯿﺔ وﯾﻌﺘﻘﺪ أ (C342R)وراﺛﯿﺔ ﺟﺪﯾﺪة 
 
 
